{"gene":"SOX10","run_date":"2026-06-10T07:46:38","timeline":{"discoveries":[{"year":1998,"finding":"SOX10 functions as a transcriptional modulator in glial cells that lacks autonomous transcriptional activity but acts synergistically with the POU domain protein Tst-1/Oct6/SCIP; synergy depends on binding to adjacent sites in target promoters and is mediated by the N-terminal regions of both proteins. SOX10 also modulates the function of Pax3 and Krox-20.","method":"Functional transcription assays, promoter binding studies, synergy assays with deletion/domain mutants","journal":"The Journal of neuroscience","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — direct functional assays with domain mapping, replicated across multiple transcription factor partners in the foundational paper","pmids":["9412504"],"is_preprint":false},{"year":1998,"finding":"Premature termination of SOX10 (Dom mutation) disrupts expression of both Sox10 and Ednrb in neural crest cells and causes loss of neural crest derivatives through apoptosis, establishing SOX10 as essential for peripheral nervous system development from the neural crest.","method":"Mouse genetic model (Dom mutation), in situ hybridization, apoptosis assays","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — loss-of-function mouse model with defined cellular phenotype (apoptosis of neural crest derivatives), widely replicated","pmids":["9425902"],"is_preprint":false},{"year":2000,"finding":"SOX10 directly binds and activates transcription of the MITF promoter; a WS4-linked mutant form of SOX10 acts as a dominant-negative repressor of MITF expression and reduces endogenous MITF protein levels, providing a molecular basis for hypopigmentation and deafness in WS4.","method":"Promoter binding assays, transcriptional activation assays, dominant-negative mutant analysis, endogenous MITF protein measurement","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — direct binding to MITF promoter demonstrated, mutant dominant-negative activity shown, functional consequence (MITF protein reduction) confirmed","pmids":["10973953"],"is_preprint":false},{"year":2002,"finding":"SOX10 binds DNA cooperatively as a dimer; specific amino acid residues immediately preceding the HMG domain are required for cooperative (dimeric) binding, which cooperates with the HMG domain in a manner dependent on determinants within the first two alpha-helices. Cooperative binding is essential for full activation of the myelin protein zero (Mpz) promoter.","method":"Mutagenesis of cooperative binding residues, DNA binding assays, promoter activation assays","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro DNA binding reconstitution plus mutagenesis and functional promoter assay, single lab but multiple orthogonal methods","pmids":["12490719"],"is_preprint":false},{"year":2003,"finding":"SOX10 maintains multipotency of neural crest stem cells by preserving both glial and neuronal potential, is required in vivo for induction of neurogenic transcription factors MASH1 and PHOX2B, and simultaneously inhibits overt neuronal differentiation (requiring higher Sox10 gene dosage than multipotency maintenance).","method":"In vitro neural crest stem cell assays, in vivo genetic analysis, gene dosage experiments","journal":"Neuron","confidence":"High","confidence_rationale":"Tier 2 / Strong — loss-of-function in vivo combined with in vitro dosage experiments, multiple orthogonal methods","pmids":["12691661"],"is_preprint":false},{"year":2007,"finding":"SOX10 dimerization domain and a newly defined central transactivation domain have distinct roles: a functional dimerization domain is required for immature Schwann cells to enter the promyelinating stage, while the central transactivation domain is uniquely required for satellite glia differentiation and Schwann cell myelination but not for early neural crest or oligodendrocyte differentiation.","method":"Hypomorphic Sox10 alleles (triple alanine substitution in dimerization domain; deletion of central transactivation domain) in mice, phenotypic analysis","journal":"Development (Cambridge, England)","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — two distinct hypomorphic alleles with domain-specific mutations analyzed in vivo, multiple cell-type phenotypes characterized","pmids":["17699610"],"is_preprint":false},{"year":2007,"finding":"SOX10 and EGR2/Krox20 interact synergistically to activate the myelin protein zero (Mpz) gene; activation of the Mpz intronic element by Egr2 requires both Sox10-binding sites; Egr1 and Egr3 also cooperate with Sox10 at this element. Dominant EGR2 neuropathy mutations disrupt EGR2/SOX10 synergy.","method":"Reporter assays, mutagenesis of binding sites, co-activation assays with Egr family members","journal":"Neuron glia biology","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — functional promoter assays with mutagenesis of binding sites, multiple Egr family members tested, disease mutations validated","pmids":["18634568"],"is_preprint":false},{"year":2007,"finding":"Olig1 physically associates with Sox10, and the Olig1/Sox10 complex activates myelin basic protein (mbp) transcription via conserved DNA sequence motifs in the mbp promoter region. In contrast, Olig2 does not bind Sox10 in zebrafish (though both OLIG1 and OLIG2 bind SOX10 in mouse).","method":"Physical binding assay (association), transcriptional reporter assays with conserved mbp promoter motifs, zebrafish and mouse comparison","journal":"The Journal of neuroscience","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — physical interaction demonstrated, functional promoter activation with defined binding sites, cross-species validation","pmids":["18160645"],"is_preprint":false},{"year":2012,"finding":"SOX10 haploinsufficiency counteracts NRAS(Q61K)-driven congenital naevus and melanoma formation in vivo; SOX10 silencing in human melanoma cells suppresses neural crest stem cell properties, inhibits proliferation and cell survival, and abolishes tumor formation in vivo.","method":"Sox10 haploinsufficiency in genetic melanoma mouse model, SOX10 siRNA knockdown in human melanoma cells, in vivo tumor formation assays","journal":"Nature cell biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis in mouse model plus loss-of-function in human cells plus in vivo tumor assay, multiple orthogonal approaches","pmids":["22772081"],"is_preprint":false},{"year":2013,"finding":"Stable SOX10 knockdown in human melanoma cells causes G1 cell cycle arrest, induces senescence, reduces MITF expression, elevates p21WAF1 and p27KIP2, leads to hypophosphorylated RB, and reduces E2F1 levels. SOX10 haploinsufficiency also reduces melanoma initiation in the Grm1(Tg) transgenic mouse model.","method":"Stable SOX10 shRNA knockdown, cell cycle analysis, western blotting, mouse genetic model","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 / Moderate — stable knockdown with defined molecular readouts (p21, p27, RB phosphorylation, E2F1) plus in vivo mouse model validation","pmids":["23913827"],"is_preprint":false},{"year":2014,"finding":"SOX10 directly binds and activates the MIA (melanoma inhibitory activity) promoter, as demonstrated by EMSA and ChIP; SOX10 inhibition reduces MIA expression and promoter activity, and ectopic MIA restores the invasion capacity of SOX10-inhibited melanoma cells, establishing MIA as a direct SOX10 target mediating invasion.","method":"RNA interference, EMSA, chromatin immunoprecipitation, luciferase reporter assays, invasion assays, rescue with ectopic MIA","journal":"The Journal of investigative dermatology","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — direct binding shown by EMSA and ChIP, functional rescue experiment performed, multiple orthogonal methods in single lab","pmids":["24608986"],"is_preprint":false},{"year":2015,"finding":"SOX9 is upregulated upon SOX10 loss in melanoma cells; SOX9 overexpression causes cell cycle arrest and apoptosis; SOX9 binds the SOX10 promoter and induces SOX10 downregulation, creating a feedback loop. SOX9 is required in vitro and in vivo for the anti-tumorigenic effect of SOX10 reduction.","method":"SOX10 knockdown, SOX9 overexpression, ChIP of SOX9 at SOX10 promoter, in vitro and in vivo tumor assays, epistasis experiments","journal":"PLoS genetics","confidence":"High","confidence_rationale":"Tier 2 / Moderate — ChIP demonstrating SOX9 binding to SOX10 promoter, genetic epistasis in vivo, multiple orthogonal methods","pmids":["25629959"],"is_preprint":false},{"year":2015,"finding":"Sox10 is specifically expressed in mammary cells with the highest stem/progenitor activity; its deletion reduces stem/progenitor competence whereas overexpression increases stem/progenitor activity and causes a mesenchymal transition in mammary cells. SOX10 acts downstream of FGF signaling.","method":"Conditional Sox10 deletion, Sox10 overexpression, mammary stem cell functional assays, organoid assays","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 / Moderate — gain- and loss-of-function in vivo and in vitro with defined functional readouts, pathway placement via FGF signaling","pmids":["26365194"],"is_preprint":false},{"year":2015,"finding":"SOX10 occupies genomic sites overlapping with active enhancers in both oligodendrocytes and Schwann cells; in oligodendrocytes, SOX10 binding sites co-occur with Olig2 and Myrf; in Schwann cells, SOX10 co-occupies sites with Egr2/Krox20. siRNA knockdown of nuclear receptors Nr2f1 and Nr2f2 reduces myelin gene expression (Mbp, Ndrg1) in Schwann cells, identifying them as SOX10 co-regulators.","method":"In vivo ChIP-Seq in spinal cord and sciatic nerve, transcriptome profiling, siRNA knockdown","journal":"Glia","confidence":"High","confidence_rationale":"Tier 2 / Moderate — in vivo ChIP-Seq with transcriptome profiling and functional siRNA validation, multiple cell types compared","pmids":["25974668"],"is_preprint":false},{"year":2016,"finding":"CHD7 interacts with SOX10 and together they target enhancers of key myelinogenic genes; Chd7 is required for proper onset of CNS myelination and remyelination.","method":"Genome-wide occupancy analysis (ChIP), transcriptome profiling, genetic mouse models","journal":"Nature neuroscience","confidence":"High","confidence_rationale":"Tier 2 / Moderate — genome-wide ChIP showing physical co-occupancy, loss-of-function phenotype, transcriptome profiling","pmids":["26928066"],"is_preprint":false},{"year":2016,"finding":"Sox10 directly activates the DNA replication licensing factor MCM5 by binding to conserved SOX10 consensus sequences in the MCM5 promoter; MCM5 overexpression partially rescues the proliferation defect caused by Sox10 knockdown in melanocytes.","method":"Sox10 knockdown (RNAi), ChIP of SOX10 at MCM5 promoter, promoter reporter assays, MCM5 rescue experiments","journal":"Journal of dermatological science","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — direct promoter binding by ChIP, functional rescue by target overexpression, multiple methods","pmids":["27955842"],"is_preprint":false},{"year":2017,"finding":"SOX10 transcriptionally activates miR335 and miR338, which in turn recognize the 3'-UTR of Sox9 mRNA to reduce Sox9 protein levels post-transcriptionally in oligodendrocytes, creating an inverse coupling between Sox10 and Sox9 levels during oligodendrocyte differentiation.","method":"Sox10 deletion in oligodendroglial cells, miRNA expression analysis, 3'-UTR reporter assays, mathematical modeling","journal":"Glia","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — direct transcriptional target identification combined with 3'-UTR validation and genetic loss-of-function, multiple orthogonal methods","pmids":["28370559"],"is_preprint":false},{"year":2018,"finding":"ERK1/2-mediated phosphorylation of SOX10 inhibits its transcriptional activity by interfering with sumoylation of SOX10 at K55, which is essential for its transcription activity. SOX10 activates FOXD3 transcription by binding a regulatory element in the FOXD3 promoter, completing an ERK1/2/SOX10/FOXD3/ERBB3 axis mediating adaptive resistance to RAF inhibitors.","method":"Phosphorylation site mutagenesis, sumoylation assays, ChIP and promoter binding assays, kinase inhibitor experiments, in vitro and in vivo knockdown","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 / Moderate — direct mutagenesis of phosphorylation (K55) and sumoylation sites, ChIP demonstrating promoter binding, multiple orthogonal methods in single lab","pmids":["29295999"],"is_preprint":false},{"year":2018,"finding":"SOX10 directly regulates PMP2 (peripheral myelin protein 2), shown by ChIP, EMSA, and luciferase reporter assays; coregulation of PMP2 by SOX10 and EGR2 in melanoma cells was found; PMP2 expression increases melanoma cell invasion.","method":"RNA sequencing after SOX10 overexpression, ChIP, EMSA, luciferase reporter assays, invasion assays","journal":"Pigment cell & melanoma research","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — direct binding to PMP2 regulatory elements shown by three independent methods (ChIP, EMSA, luciferase), functional invasion assay","pmids":["30506895"],"is_preprint":false},{"year":2018,"finding":"SOX10 phosphorylation sites S24, S45, and T240 (within MAPK/CDK binding motifs) were identified by mass spectrometry and shown to affect SOX10 transcriptional activation on target promoters, subcellular localization, and protein stability in melanoma cells.","method":"Mass spectrometry phosphoproteomics, site-directed mutagenesis, transcriptional activation assays, subcellular localization imaging, protein stability assays","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 1–2 / Weak — mass spectrometry identification with mutagenesis follow-up, but single lab with limited functional depth per site","pmids":["29315345"],"is_preprint":false},{"year":2019,"finding":"Sox10 is essential for maintenance and differentiation of epithelial KIT+FGFR2b+ progenitors into secretory units (acinar, myoepithelial, and intercalated duct cells) in exocrine glands; genetic deletion of epithelial Sox10 leads to loss of secretory units; Sox10 overexpression in ductal progenitors enhances plasticity toward KIT+ progenitors and secretory unit differentiation.","method":"Genetic conditional deletion of Sox10 in epithelial cells, Sox10 overexpression, lineage tracing, organoid assays","journal":"Stem cell reports","confidence":"High","confidence_rationale":"Tier 2 / Moderate — conditional genetic deletion and overexpression in vivo, multiple gland types examined, defined cellular phenotypes","pmids":["30713042"],"is_preprint":false},{"year":2020,"finding":"Myrf cooperates with Sox10 to induce genes required for oligodendrocyte differentiation and myelin formation through joint binding to the same regulatory regions; Myrf also inhibits Sox10 activity on earlier oligodendroglial genes through physical interaction with Sox10 followed by sequestration (on genes lacking Myrf binding sites).","method":"ChIP-Seq for binding site characterization, co-immunoprecipitation/physical interaction assays, transcriptional reporter assays, mutagenesis of Myrf DNA-binding sites","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — genome-wide binding site analysis combined with physical interaction and functional reporter assays, two distinct mechanisms defined","pmids":["31828317"],"is_preprint":false},{"year":2021,"finding":"Akt phosphorylates FoxO1, and phosphorylated FoxO1 is required for Sox10 promoter activity; Akt triple knockout in oligodendrocyte lineage cells causes complete loss of mature oligodendrocytes with downregulation of Sox10, and mutant FoxO1 without Akt phosphorylation epitopes is enriched at the Sox10 promoter.","method":"Oligodendrocyte-specific Akt1/2/3 triple conditional knockout mice, FoxO1 phospho-site mutagenesis, Sox10 promoter activity assays, ChIP of FoxO1 at Sox10 promoter","journal":"The Journal of neuroscience","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — conditional triple knockout mouse model, FoxO1 mutagenesis at Akt phosphorylation sites, ChIP at Sox10 promoter, multiple orthogonal methods","pmids":["34385359"],"is_preprint":false},{"year":2021,"finding":"SOX10 represses IRF1 transcription via direct induction of the negative regulator IRF4, establishing a SOX10-IRF4-IRF1 axis that regulates PD-L1 expression independently of the JAK-STAT pathway in melanoma cells.","method":"Genetic and pharmacologic SOX10 loss-of-function, IRF4 and IRF1 expression analysis, PD-L1 regulation assays","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic and pharmacologic approaches in single lab; direct binding of SOX10 to IRF4 regulatory elements not explicitly demonstrated in the abstract","pmids":["34728538"],"is_preprint":false},{"year":2021,"finding":"SOX10 positively regulates HVEM and CEACAM1 expression in melanoma; Sox10 knockout reduces tumor growth in immune-competent models in a manner dependent partly on CD8+ T cells, demonstrating that SOX10 controls immune checkpoint protein expression and anti-tumor immunity.","method":"Sox10 knockout mouse models (immune-competent and immune-deficient), CD8+ T cell depletion, CEACAM1 and HVEM expression modulation","journal":"Cell reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo Sox10 knockout with immune cell depletion epistasis, but direct transcriptional regulation of HVEM/CEACAM1 by SOX10 not demonstrated mechanistically","pmids":["34879275"],"is_preprint":false},{"year":2023,"finding":"Recurrent in-frame insertion/deletion mutations in SOX10 found in schwannomas retain DNA binding capacity but have impaired transactivation of glial differentiation and myelination gene programs, driving schwannoma formation by impeding Schwann cell differentiation.","method":"ChIP-Seq, EMSA, luciferase reporter assays, RNA sequencing in fetal glial cells transduced with wild-type and mutant SOX10","journal":"Neuro-oncology","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — multiple orthogonal methods (ChIP-Seq, EMSA, luciferase, RNA-Seq) directly testing mutant versus wild-type SOX10 function in the same study","pmids":["37436963"],"is_preprint":false},{"year":2013,"finding":"SOX10 modulates expression of β1-integrins (Itgb1) in enteric neural crest cells; double mutants for Sox10 and beta1-integrin show increased intestinal aganglionosis and impaired enteric neural crest cell migration with reduced speed and altered directionality, indicating SOX10 mediates enteric neural crest cell adhesion and migration through β1-integrin regulation.","method":"Genetic double mutant mouse analysis, video-microscopy of cell migration, β1-integrin expression analysis upon SOX10 modulation","journal":"Developmental biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis in double-mutant mouse model with live cell migration imaging, but direct transcriptional regulation of Itgb1 by SOX10 not fully established","pmids":["23608456"],"is_preprint":false},{"year":2014,"finding":"SOX10 directly activates the S100B promoter through three core response elements with SOX motifs in the S100B promoter and intron 1; SOX10 knockdown suppresses S100B expression and enhances Schwann cell proliferation; S100B knockdown impairs myelination in dorsal root ganglia co-cultures.","method":"SOX10 overexpression/knockdown, promoter deletion/mutation analysis identifying SOX10 response elements, shRNA knockdown of S100B, DRG myelination assay","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — direct identification of three SOX10 response elements in S100B promoter/intron1, gain/loss-of-function with functional myelination readout","pmids":["25536222"],"is_preprint":false},{"year":2023,"finding":"SOX10 binds the miR-29a-3p promoter region to increase miR-29a-3p expression; miR-29a-3p in turn targets and limits ACSL4 transcription, thereby inhibiting ferroptosis of hippocampal neurons in an ICH model.","method":"ChIP assay, dual-luciferase reporter assays, miR-29a-3p overexpression/knockdown, ACSL4 expression analysis, ferroptosis assays","journal":"Journal of neurophysiology","confidence":"Medium","confidence_rationale":"Tier 1–2 / Weak — ChIP and dual-luciferase confirm SOX10 binding to miR-29a-3p promoter, but single lab, in vitro ICH model only","pmids":["36919939"],"is_preprint":false},{"year":2006,"finding":"Genetic interaction analysis of Sox10 with Ednrb and Edn3 double mutant mice shows that balanced Sox10 and endothelin signaling is required for normal ENS and melanocyte development; partial loss of Ednrb in Sox10 heterozygous mice impairs colonisation of the gut by enteric crest cells without increasing apoptosis or altering differentiation, indicating a migration/survival role.","method":"Sox10;Ednrb and Sox10;Edn3 double mutant mouse phenotype analysis, apoptosis assays, cell proliferation assays, differentiation marker analysis","journal":"Developmental biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis using double mutant mice with multiple cellular readouts, but mechanistic link between SOX10 and Ednrb signaling not defined at molecular level","pmids":["16650841"],"is_preprint":false},{"year":2005,"finding":"A 15.9 kb deletion 47.3 kb upstream of Sox10 removes conserved non-coding sequences with strong enhancer potential in melanocytes and reduces Sox10 expression in vivo, causing an enteric aganglionosis and melanocyte loss phenotype (WS4-like), establishing that long-range regulatory elements are required for Sox10 expression.","method":"Comparative genomic sequence analysis, in vitro enhancer assay in melanocytes, transgene-insertion mouse model with Sox10 expression analysis","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo deletion model with expression analysis and in vitro enhancer validation, but enhancer assignment is partial","pmids":["16330480"],"is_preprint":false},{"year":2021,"finding":"In vivo ATAC-Seq of zebrafish melanoma tumors identified recurrently open chromatin domains as sox10 enhancers; a conserved ~200 bp region 23 kb upstream of sox10 (peak5) containing dimeric SoxE/Sox10 binding sites drives expression in neural crest and melanoma; deletion of the endogenous peak5 locus decreases embryonic sox10 expression and disrupts adult stripe patterning.","method":"ATAC-Seq, EGFP reporter assays in vivo, binding site mutagenesis, endogenous locus deletion in zebrafish","journal":"Communications biology","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — ATAC-Seq combined with in vivo reporter, binding site mutagenesis, and endogenous locus deletion, multiple orthogonal methods","pmids":["34099848"],"is_preprint":false},{"year":2015,"finding":"Ets1 activates an enhancer critical for Sox10 expression in neural crest-derived structures; this activation is inhibited by the variable spotting Ets1 G102E mutation; Ets1 and Sox10 interact synergistically in melanocyte and enteric ganglia development (double heterozygotes show greater hypopigmentation than additive effects of single heterozygotes).","method":"Genetic epistasis (double heterozygous mice), enhancer reporter assays, mutation analysis","journal":"Developmental biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis in mouse model with functional enhancer validation, but direct Ets1-Sox10 protein interaction not demonstrated","pmids":["25912689"],"is_preprint":false}],"current_model":"SOX10 is a dimerizing HMG-box transcription factor that acts as a context-dependent transcriptional activator and co-regulator: it directly binds target gene promoters/enhancers (MITF, Mpz, MBP, MIA, PMP2, S100B, MCM5, FOXD3, miR-29a-3p) to activate transcription, cooperates synergistically with cell-type-specific partners (Oct6/SCIP, Olig1, EGR2, Myrf, CHD7) through protein–protein interactions that require its N-terminal and central transactivation domains, and is regulated post-translationally by ERK-mediated phosphorylation (which blocks sumoylation at K55, reducing transcriptional activity) and by Akt-dependent FoxO1 phosphorylation (which controls Sox10 promoter activity); its dimeric DNA-binding mode requires conserved residues flanking the HMG domain and is essential for full target gene activation; loss of SOX10 in neural crest progenitors causes apoptosis and loss of PNS/melanocyte derivatives, while in differentiated glia it controls the switch from oligodendrocyte precursor to myelinating states partly through transcriptional upregulation of miR335/miR338 that reciprocally suppress Sox9."},"narrative":{"mechanistic_narrative":"SOX10 is a dimerizing HMG-box transcription factor that governs the specification, survival, and differentiation of neural crest derivatives and their glial and melanocytic progeny [PMID:9425902, PMID:12691661]. In neural crest stem cells it preserves multipotency and is required for induction of neurogenic factors MASH1 and PHOX2B, while its loss triggers apoptosis and depletion of peripheral nervous system and melanocyte lineages [PMID:9425902, PMID:12691661]. SOX10 has little autonomous transactivation capacity and operates combinatorially, binding adjacent promoter/enhancer sites and acting synergistically with cell-type-specific partners through its N-terminal and central transactivation domains: Oct6/SCIP, Pax3 and Krox20 in glia [PMID:9412504], EGR2/Krox20 and the nuclear receptors NR2F1/NR2F2 at Schwann-cell myelin genes [PMID:18634568, PMID:25974668], Olig1 and the chromatin remodeler CHD7 at oligodendrocyte myelin enhancers [PMID:18160645, PMID:26928066], and Myrf, which both co-activates late myelination genes and sequesters SOX10 from earlier oligodendroglial targets [PMID:31828317]. Its DNA-binding is cooperative and dimeric, requiring residues flanking the HMG domain; this dimerization is essential for full activation of the myelin protein zero (Mpz) promoter and for Schwann cells to enter the promyelinating stage, whereas a distinct central transactivation domain is uniquely needed for satellite glia and Schwann cell myelination [PMID:12490719, PMID:17699610]. SOX10 directly activates an extended target repertoire including MITF, MBP, MIA, PMP2, S100B, MCM5, FOXD3, and the microRNAs miR335/miR338 (which reciprocally suppress Sox9) and miR-29a-3p, thereby controlling pigmentation, myelin gene programs, proliferation, and lineage stability [PMID:10973953, PMID:18160645, PMID:24608986, PMID:27955842, PMID:28370559, PMID:29295999, PMID:30506895, PMID:25536222, PMID:36919939]. SOX10 activity is post-translationally tuned: ERK1/2 phosphorylation blocks sumoylation at K55 to dampen transcriptional output as part of an ERK/SOX10/FOXD3/ERBB3 axis driving RAF-inhibitor resistance, and Akt-dependent FoxO1 phosphorylation controls Sox10 promoter activity in the oligodendrocyte lineage [PMID:29295999, PMID:34385359]. In disease, dominant-negative WS4-linked mutants repress MITF [PMID:10973953], SOX10 is a melanoma dependency whose loss induces senescence and engages a counter-regulatory SOX9 loop [PMID:22772081, PMID:23913827, PMID:25629959], and recurrent indel mutations that retain DNA binding but lose transactivation drive schwannoma by blocking glial differentiation [PMID:37436963].","teleology":[{"year":1998,"claim":"Established that SOX10 is not an autonomous activator but a combinatorial transcriptional modulator, reframing how its glial gene control should be understood.","evidence":"Transcription and synergy assays with domain-deletion mutants and POU partner Tst-1/Oct6/SCIP in glial cells","pmids":["9412504"],"confidence":"High","gaps":["Did not define the full set of synergistic partners","N-terminal interaction surface mapped only coarsely"]},{"year":1998,"claim":"Demonstrated that SOX10 is essential for neural crest derivative survival, establishing its developmental requirement in PNS formation.","evidence":"Dom premature-termination mutation in mice with in situ hybridization and apoptosis assays","pmids":["9425902"],"confidence":"High","gaps":["Mechanistic basis of apoptosis not resolved","Relationship to Ednrb regulation correlative"]},{"year":2000,"claim":"Identified MITF as a direct SOX10 target and provided the molecular basis for WS4 pigmentation/deafness via dominant-negative mutant action.","evidence":"MITF promoter binding and activation assays plus dominant-negative WS4 mutant analysis and endogenous MITF measurement","pmids":["10973953"],"confidence":"High","gaps":["Other WS4-relevant targets not addressed","Cofactor requirements at MITF promoter not defined"]},{"year":2002,"claim":"Defined the cooperative dimeric DNA-binding mode and showed it is required for full myelin gene activation, explaining a key biochemical feature of SOX10 function.","evidence":"Mutagenesis of residues flanking the HMG domain with DNA-binding and Mpz promoter assays","pmids":["12490719"],"confidence":"High","gaps":["Structural model of the dimer not determined","In vivo requirement tested only later"]},{"year":2003,"claim":"Showed SOX10 maintains neural crest multipotency in a dosage-dependent manner, separating its stem-cell maintenance role from differentiation control.","evidence":"In vitro NCSC assays and in vivo gene-dosage genetics with MASH1/PHOX2B readouts","pmids":["12691661"],"confidence":"High","gaps":["Direct targets mediating multipotency not identified","Dosage thresholds molecularly undefined"]},{"year":2005,"claim":"Demonstrated that long-range upstream enhancers are required for proper Sox10 expression, expanding the disease model beyond coding mutations.","evidence":"15.9 kb upstream deletion mouse model with enhancer assays and expression analysis","pmids":["16330480"],"confidence":"Medium","gaps":["Enhancer assignment partial","Trans-factors binding the enhancer not fully identified"]},{"year":2006,"claim":"Placed SOX10 in balanced cooperation with endothelin signaling for enteric and melanocyte development, implicating migration/survival rather than differentiation.","evidence":"Sox10;Ednrb and Sox10;Edn3 double-mutant mouse analysis with apoptosis/proliferation/differentiation readouts","pmids":["16650841"],"confidence":"Medium","gaps":["Molecular link between SOX10 and endothelin signaling undefined","Direct transcriptional connection not shown"]},{"year":2007,"claim":"Separated SOX10 dimerization and central transactivation domains as functionally distinct, mapping which glial transitions each domain controls.","evidence":"Two hypomorphic Sox10 alleles (dimerization triple-alanine; central TAD deletion) analyzed in mice","pmids":["17699610"],"confidence":"High","gaps":["Domain-specific cofactor partners not fully resolved","Direct targets per domain not enumerated"]},{"year":2007,"claim":"Established EGR2/SOX10 synergy at the Mpz gene and linked dominant EGR2 neuropathy mutations to disrupted synergy, providing a mechanistic disease readout.","evidence":"Reporter assays with binding-site mutagenesis and co-activation with Egr family members","pmids":["18634568"],"confidence":"High","gaps":["Physical EGR2-SOX10 contact surface not mapped","Genome-wide co-targets defined only later"]},{"year":2008,"claim":"Identified Olig1 as a physical SOX10 partner activating mbp, revealing a CNS-specific cooperative module distinct from the Schwann-cell program.","evidence":"Physical association assays and mbp reporter assays with conserved motifs, zebrafish/mouse comparison","pmids":["18160645"],"confidence":"High","gaps":["Species difference in Olig2 binding unexplained","Stoichiometry of the complex unknown"]},{"year":2012,"claim":"Established SOX10 as a melanoma dependency required for tumor formation and neural crest stem-cell properties, extending its developmental role to cancer.","evidence":"Sox10 haploinsufficiency in NRAS(Q61K) mouse model plus siRNA knockdown and in vivo tumor assays in human cells","pmids":["22772081"],"confidence":"High","gaps":["Direct effector targets of the tumor phenotype not fully defined here","Mechanism of stem-cell property maintenance unresolved"]},{"year":2013,"claim":"Defined the cell-cycle consequences of SOX10 loss in melanoma (G1 arrest, senescence, p21/p27 induction, RB hypophosphorylation), connecting SOX10 to proliferative control.","evidence":"Stable shRNA knockdown with cell-cycle and western analyses plus Grm1(Tg) mouse model","pmids":["23913827"],"confidence":"High","gaps":["Direct vs indirect regulation of cell-cycle effectors not separated","MITF dependence of the arrest not fully dissected"]},{"year":2013,"claim":"Linked SOX10 to enteric neural crest migration through β1-integrin regulation, framing a cell-adhesion/migration function.","evidence":"Sox10;Itgb1 double-mutant mice with video-microscopy of migration","pmids":["23608456"],"confidence":"Medium","gaps":["Direct transcriptional regulation of Itgb1 not established","Genetic interaction may be indirect"]},{"year":2014,"claim":"Identified MIA as a direct SOX10 target mediating melanoma invasion, providing a functional rescue-validated invasion effector.","evidence":"EMSA, ChIP, luciferase, invasion assays with ectopic MIA rescue","pmids":["24608986"],"confidence":"High","gaps":["Cofactors at the MIA promoter not defined","In vivo invasion contribution not tested"]},{"year":2014,"claim":"Established S100B as a direct SOX10 target through defined response elements, linking SOX10 to Schwann cell proliferation control and myelination.","evidence":"Promoter/intron deletion-mutation mapping, gain/loss-of-function, and DRG myelination co-culture","pmids":["25536222"],"confidence":"High","gaps":["S100B downstream signaling in myelination not fully resolved","In vivo requirement not tested"]},{"year":2015,"claim":"Mapped SOX10 genome-wide enhancer occupancy in two glial lineages and identified lineage-specific co-regulators (Olig2/Myrf vs Egr2; NR2F1/2), unifying its cell-type-specific partnerships.","evidence":"In vivo ChIP-Seq in spinal cord and sciatic nerve with transcriptome profiling and siRNA validation","pmids":["25974668"],"confidence":"High","gaps":["Direct vs cooperative binding contributions not parsed at all sites","NR2F1/2 contact with SOX10 not biochemically shown"]},{"year":2015,"claim":"Established a SOX10-SOX9 reciprocal feedback loop as the basis of the anti-tumorigenic effect of SOX10 loss in melanoma.","evidence":"SOX10 knockdown, SOX9 overexpression, ChIP of SOX9 at SOX10 promoter, in vivo epistasis","pmids":["25629959"],"confidence":"High","gaps":["How SOX10 normally restrains SOX9 transcriptionally not fully defined","Generality across melanoma subtypes untested"]},{"year":2015,"claim":"Extended SOX10 function to mammary epithelial stem/progenitor competence downstream of FGF signaling, broadening its role beyond neural crest lineages.","evidence":"Conditional deletion and overexpression with mammary stem-cell and organoid assays","pmids":["26365194"],"confidence":"High","gaps":["Direct SOX10 targets in mammary cells not identified","Mechanism of FGF-to-SOX10 coupling unresolved"]},{"year":2015,"claim":"Showed Ets1 activates a neural-crest Sox10 enhancer and interacts synergistically with Sox10, identifying an upstream regulatory input.","evidence":"Double-heterozygous mice, enhancer reporter assays, G102E mutation analysis","pmids":["25912689"],"confidence":"Medium","gaps":["Direct Ets1-Sox10 protein interaction not demonstrated","Synergy mechanism molecularly undefined"]},{"year":2016,"claim":"Identified MCM5 as a direct SOX10 target linking SOX10 to DNA replication licensing and melanocyte proliferation.","evidence":"RNAi knockdown, ChIP at MCM5 promoter, reporter assays, MCM5 rescue","pmids":["27955842"],"confidence":"High","gaps":["Other replication targets not surveyed","In vivo proliferation contribution untested"]},{"year":2016,"claim":"Established CHD7 as a SOX10 chromatin-remodeling partner at myelinogenic enhancers required for CNS myelination and remyelination.","evidence":"Genome-wide ChIP co-occupancy, transcriptome profiling, genetic mouse models","pmids":["26928066"],"confidence":"High","gaps":["Biochemical SOX10-CHD7 contact not mapped","Remyelination mechanism not fully dissected"]},{"year":2017,"claim":"Revealed that SOX10 activates miR335/miR338 to post-transcriptionally suppress Sox9, formalizing an inverse Sox10-Sox9 coupling during oligodendrocyte differentiation.","evidence":"Sox10 deletion in oligodendroglia, miRNA profiling, 3'-UTR reporters, mathematical modeling","pmids":["28370559"],"confidence":"High","gaps":["Direct vs indirect miRNA promoter activation not fully separated","In vivo necessity of the loop untested"]},{"year":2018,"claim":"Defined ERK1/2 phosphorylation as a switch that blocks K55 sumoylation to suppress SOX10 activity, and placed SOX10/FOXD3 in a RAF-inhibitor resistance axis.","evidence":"Phospho- and sumo-site mutagenesis, ChIP, kinase inhibitors, in vitro/in vivo knockdown","pmids":["29295999"],"confidence":"High","gaps":["Stoichiometry of phospho-sumo crosstalk in vivo unquantified","Other sumoylation-dependent targets not surveyed"]},{"year":2018,"claim":"Identified PMP2 as a direct SOX10/EGR2 co-target promoting melanoma invasion, extending myelin-gene regulation into the tumor context.","evidence":"RNA-Seq after overexpression, ChIP, EMSA, luciferase, invasion assays","pmids":["30506895"],"confidence":"High","gaps":["In vivo invasion role untested","Mechanism of PMP2-driven invasion undefined"]},{"year":2018,"claim":"Mapped additional SOX10 phosphosites (S24, S45, T240) affecting activity, localization, and stability, broadening the post-translational regulatory map.","evidence":"Mass spectrometry phosphoproteomics, site mutagenesis, activity/localization/stability assays","pmids":["29315345"],"confidence":"Medium","gaps":["Limited functional depth per site","Responsible kinases not definitively assigned"]},{"year":2020,"claim":"Showed Myrf has a dual cooperative/sequestering relationship with SOX10, explaining how the same factor can both promote late and inhibit early oligodendroglial gene programs.","evidence":"ChIP-Seq, co-immunoprecipitation, reporter assays, Myrf binding-site mutagenesis","pmids":["31828317"],"confidence":"High","gaps":["Structural basis of sequestration unknown","Quantitative balance between modes in vivo unresolved"]},{"year":2019,"claim":"Demonstrated SOX10 is required for exocrine gland epithelial KIT+FGFR2b+ progenitor maintenance and secretory differentiation, generalizing its progenitor-control function.","evidence":"Conditional deletion and overexpression with lineage tracing and organoids","pmids":["30713042"],"confidence":"High","gaps":["Direct epithelial SOX10 targets not identified","FGFR2b-SOX10 coupling mechanism undefined"]},{"year":2021,"claim":"Identified an Akt-FoxO1 input controlling Sox10 promoter activity required for oligodendrocyte maturation, defining an upstream signaling control of SOX10 expression.","evidence":"Oligodendrocyte Akt1/2/3 triple knockout, FoxO1 phospho-site mutagenesis, ChIP at Sox10 promoter","pmids":["34385359"],"confidence":"High","gaps":["How phospho-FoxO1 enables Sox10 transcription mechanistically unclear","Other Akt targets contributing not excluded"]},{"year":2021,"claim":"Linked SOX10 to immune evasion via a SOX10-IRF4-IRF1 axis regulating PD-L1 independently of JAK-STAT.","evidence":"Genetic and pharmacologic SOX10 loss with IRF4/IRF1 and PD-L1 readouts","pmids":["34728538"],"confidence":"Medium","gaps":["Direct SOX10 binding to IRF4 regulatory elements not shown","In vivo immune relevance addressed separately"]},{"year":2021,"claim":"Showed SOX10 controls immune checkpoint proteins HVEM/CEACAM1 and CD8+ T-cell-dependent tumor growth, connecting SOX10 to anti-tumor immunity.","evidence":"Sox10 knockout in immune-competent/deficient mice with CD8+ depletion and checkpoint modulation","pmids":["34879275"],"confidence":"Medium","gaps":["Direct transcriptional regulation of HVEM/CEACAM1 not demonstrated","Mechanism of immune coupling indirect"]},{"year":2021,"claim":"Identified an upstream peak5 enhancer with dimeric SoxE binding sites driving sox10 in neural crest and melanoma, linking enhancer regulation to pigment patterning and tumor chromatin state.","evidence":"ATAC-Seq, in vivo EGFP reporters, binding-site mutagenesis, endogenous locus deletion in zebrafish","pmids":["34099848"],"confidence":"High","gaps":["Mammalian conservation of peak5 not established here","Trans-factors beyond SoxE not fully defined"]},{"year":2023,"claim":"Established that recurrent SOX10 indel mutations retain DNA binding but lose transactivation to block Schwann cell differentiation, defining a schwannoma driver mechanism.","evidence":"ChIP-Seq, EMSA, luciferase, RNA-Seq comparing wild-type and mutant SOX10 in fetal glial cells","pmids":["37436963"],"confidence":"High","gaps":["Cofactor loss underlying transactivation defect not pinpointed","In vivo tumorigenesis from these alleles untested"]},{"year":2023,"claim":"Showed SOX10 binds the miR-29a-3p promoter to suppress ACSL4 and limit neuronal ferroptosis, extending SOX10 regulation to a neuroprotective miRNA axis.","evidence":"ChIP, dual-luciferase, miR-29a-3p gain/loss, ACSL4 and ferroptosis assays in an ICH model","pmids":["36919939"],"confidence":"Medium","gaps":["Single-lab in vitro ICH model only","In vivo relevance not established"]},{"year":null,"claim":"How SOX10's combinatorial partner choice, dimeric binding, and post-translational modification state are integrated to select between progenitor-maintenance, myelination, and oncogenic gene programs in a given cell remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model linking phospho/sumo state to partner selection","Structural basis of context-specific complexes undefined","Quantitative dosage thresholds across lineages not mapped"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,2,6,7,10,15,16,17,18,21,25,27,28]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[2,3,10,15,18,25,27,31]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[17,19]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[0,2,6,7,16,17,21]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[1,4,5,20,27]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[2,8,9,11,25]}],"complexes":[],"partners":["EGR2","OLIG1","MYRF","CHD7","OCT6/POU3F1","PAX3","NR2F1","SOX9"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P56693","full_name":"Transcription factor SOX-10","aliases":[],"length_aa":466,"mass_kda":49.9,"function":"Transcription factor that plays a central role in developing and mature glia (By similarity). Specifically activates expression of myelin genes, during oligodendrocyte (OL) maturation, such as DUSP15 and MYRF, thereby playing a central role in oligodendrocyte maturation and CNS myelination (By similarity). Once induced, MYRF cooperates with SOX10 to implement the myelination program (By similarity). Transcriptional activator of MITF, acting synergistically with PAX3 (PubMed:21965087). Transcriptional activator of MBP, via binding to the gene promoter (By similarity)","subcellular_location":"Cytoplasm; Nucleus; Mitochondrion outer membrane","url":"https://www.uniprot.org/uniprotkb/P56693/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/SOX10","classification":"Not Classified","n_dependent_lines":257,"n_total_lines":1208,"dependency_fraction":0.21274834437086093},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/SOX10","total_profiled":1310},"omim":[{"mim_id":"620675","title":"LEUKODYSTROPHY, HYPOMYELINATING, 27; HLD27","url":"https://www.omim.org/entry/620675"},{"mim_id":"619701","title":"YOON-BELLEN NEURODEVELOPMENTAL SYNDROME; YOBELN","url":"https://www.omim.org/entry/619701"},{"mim_id":"617513","title":"OXOGLUTARATE DEHYDROGENASE-LIKE PROTEIN; OGDHL","url":"https://www.omim.org/entry/617513"},{"mim_id":"616895","title":"SURVIVAL-ASSOCIATED MITOCHONDRIAL MELANOMA-SPECIFIC ONCOGENIC NONCODING RNA; SAMMSON","url":"https://www.omim.org/entry/616895"},{"mim_id":"616404","title":"POLYMERASE I, RNA, SUBUNIT A; POLR1A","url":"https://www.omim.org/entry/616404"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"}],"tissue_specificity":"Group enriched","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"brain","ntpm":151.8},{"tissue":"salivary gland","ntpm":105.2}],"url":"https://www.proteinatlas.org/search/SOX10"},"hgnc":{"alias_symbol":["DOM","WS4","WS2E","SOX-10"],"prev_symbol":[]},"alphafold":{"accession":"P56693","domains":[{"cath_id":"1.10.30.10","chopping":"108-169","consensus_level":"medium","plddt":93.2945,"start":108,"end":169}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P56693","model_url":"https://alphafold.ebi.ac.uk/files/AF-P56693-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P56693-F1-predicted_aligned_error_v6.png","plddt_mean":55.84},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=SOX10","jax_strain_url":"https://www.jax.org/strain/search?query=SOX10"},"sequence":{"accession":"P56693","fasta_url":"https://rest.uniprot.org/uniprotkb/P56693.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P56693/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P56693"}},"corpus_meta":[{"pmid":"9412504","id":"PMC_9412504","title":"Sox10, a novel transcriptional modulator in glial cells.","date":"1998","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/9412504","citation_count":646,"is_preprint":false},{"pmid":"9425902","id":"PMC_9425902","title":"Sox10 mutation disrupts neural crest development in Dom Hirschsprung mouse model.","date":"1998","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/9425902","citation_count":625,"is_preprint":false},{"pmid":"12691661","id":"PMC_12691661","title":"SOX10 maintains multipotency and inhibits neuronal differentiation of neural crest stem cells.","date":"2003","source":"Neuron","url":"https://pubmed.ncbi.nlm.nih.gov/12691661","citation_count":461,"is_preprint":false},{"pmid":"18636017","id":"PMC_18636017","title":"Sox10: a pan-schwannian and melanocytic marker.","date":"2008","source":"The American journal of surgical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/18636017","citation_count":288,"is_preprint":false},{"pmid":"22495377","id":"PMC_22495377","title":"Sox10 and S100 in the diagnosis of soft-tissue neoplasms.","date":"2012","source":"Applied immunohistochemistry & molecular morphology : AIMM","url":"https://pubmed.ncbi.nlm.nih.gov/22495377","citation_count":242,"is_preprint":false},{"pmid":"22772081","id":"PMC_22772081","title":"Sox10 promotes the formation and maintenance of giant congenital naevi and melanoma.","date":"2012","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/22772081","citation_count":221,"is_preprint":false},{"pmid":"17999358","id":"PMC_17999358","title":"Deletions at the SOX10 gene locus cause Waardenburg syndrome types 2 and 4.","date":"2007","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/17999358","citation_count":211,"is_preprint":false},{"pmid":"16927299","id":"PMC_16927299","title":"Sorting out Sox10 functions in neural crest development.","date":"2006","source":"BioEssays : news and reviews in molecular, cellular and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/16927299","citation_count":195,"is_preprint":false},{"pmid":"15930386","id":"PMC_15930386","title":"DNA methylation status of SOX10 correlates with its downregulation and oligodendrocyte dysfunction in schizophrenia.","date":"2005","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/15930386","citation_count":186,"is_preprint":false},{"pmid":"26928066","id":"PMC_26928066","title":"Chd7 cooperates with Sox10 and regulates the onset of CNS myelination and remyelination.","date":"2016","source":"Nature neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/26928066","citation_count":149,"is_preprint":false},{"pmid":"10973953","id":"PMC_10973953","title":"Direct regulation of the Microphthalmia promoter by Sox10 links Waardenburg-Shah syndrome (WS4)-associated hypopigmentation and deafness to WS2.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10973953","citation_count":145,"is_preprint":false},{"pmid":"18160645","id":"PMC_18160645","title":"Olig1 and Sox10 interact synergistically to drive myelin basic protein transcription in oligodendrocytes.","date":"2007","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/18160645","citation_count":143,"is_preprint":false},{"pmid":"10077527","id":"PMC_10077527","title":"The Sox10(Dom) mouse: modeling the genetic variation of Waardenburg-Shah (WS4) syndrome.","date":"1999","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/10077527","citation_count":123,"is_preprint":false},{"pmid":"23197006","id":"PMC_23197006","title":"SOX10 expression in malignant melanoma, carcinoma, and normal tissues.","date":"2013","source":"Applied immunohistochemistry & molecular morphology : AIMM","url":"https://pubmed.ncbi.nlm.nih.gov/23197006","citation_count":112,"is_preprint":false},{"pmid":"16650841","id":"PMC_16650841","title":"Interactions between Sox10, Edn3 and Ednrb during enteric nervous system and melanocyte development.","date":"2006","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/16650841","citation_count":105,"is_preprint":false},{"pmid":"26365194","id":"PMC_26365194","title":"Sox10 Regulates Stem/Progenitor and Mesenchymal Cell States in Mammary Epithelial Cells.","date":"2015","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/26365194","citation_count":100,"is_preprint":false},{"pmid":"9720918","id":"PMC_9720918","title":"Expression of the SOX10 gene during human development.","date":"1998","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/9720918","citation_count":95,"is_preprint":false},{"pmid":"25974668","id":"PMC_25974668","title":"Differential Sox10 genomic occupancy in myelinating glia.","date":"2015","source":"Glia","url":"https://pubmed.ncbi.nlm.nih.gov/25974668","citation_count":93,"is_preprint":false},{"pmid":"23644063","id":"PMC_23644063","title":"The role of SOX10 during enteric nervous system development.","date":"2013","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/23644063","citation_count":86,"is_preprint":false},{"pmid":"34667088","id":"PMC_34667088","title":"SOX10: 20 years of phenotypic plurality and current understanding of its developmental function.","date":"2021","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/34667088","citation_count":82,"is_preprint":false},{"pmid":"17699610","id":"PMC_17699610","title":"Hypomorphic Sox10 alleles reveal novel protein functions and unravel developmental differences in glial lineages.","date":"2007","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/17699610","citation_count":82,"is_preprint":false},{"pmid":"33339831","id":"PMC_33339831","title":"Glioblastoma epigenome profiling identifies SOX10 as a master regulator of molecular tumour subtype.","date":"2020","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/33339831","citation_count":81,"is_preprint":false},{"pmid":"25629959","id":"PMC_25629959","title":"Antagonistic cross-regulation between Sox9 and Sox10 controls an anti-tumorigenic program in melanoma.","date":"2015","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/25629959","citation_count":81,"is_preprint":false},{"pmid":"23913827","id":"PMC_23913827","title":"SOX10 ablation arrests cell cycle, induces senescence, and suppresses melanomagenesis.","date":"2013","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/23913827","citation_count":79,"is_preprint":false},{"pmid":"24608986","id":"PMC_24608986","title":"SOX10 promotes melanoma cell invasion by regulating melanoma inhibitory activity.","date":"2014","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/24608986","citation_count":74,"is_preprint":false},{"pmid":"35296667","id":"PMC_35296667","title":"Targeting SOX10-deficient cells to reduce the dormant-invasive phenotype state in melanoma.","date":"2022","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/35296667","citation_count":73,"is_preprint":false},{"pmid":"34480425","id":"PMC_34480425","title":"Using the lineage determinants Olig2 and Sox10 to explore transcriptional regulation of oligodendrocyte development.","date":"2021","source":"Developmental neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/34480425","citation_count":73,"is_preprint":false},{"pmid":"19570850","id":"PMC_19570850","title":"Disc1 regulates foxd3 and sox10 expression, affecting neural crest migration and differentiation.","date":"2009","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/19570850","citation_count":71,"is_preprint":false},{"pmid":"30616040","id":"PMC_30616040","title":"Disparate effects of DOM extracted from coastal seawaters and freshwaters on photodegradation of 2,4-Dihydroxybenzophenone.","date":"2018","source":"Water research","url":"https://pubmed.ncbi.nlm.nih.gov/30616040","citation_count":70,"is_preprint":false},{"pmid":"23799842","id":"PMC_23799842","title":"Diagnostic SOX10 gene signatures in salivary adenoid cystic and breast basal-like carcinomas.","date":"2013","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/23799842","citation_count":67,"is_preprint":false},{"pmid":"35413381","id":"PMC_35413381","title":"TRPS1, GATA3, and SOX10 expression in triple-negative breast carcinoma.","date":"2022","source":"Human pathology","url":"https://pubmed.ncbi.nlm.nih.gov/35413381","citation_count":65,"is_preprint":false},{"pmid":"29295999","id":"PMC_29295999","title":"ERK-mediated phosphorylation regulates SOX10 sumoylation and targets expression in mutant BRAF melanoma.","date":"2018","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/29295999","citation_count":65,"is_preprint":false},{"pmid":"18634568","id":"PMC_18634568","title":"Interactions of Sox10 and Egr2 in myelin gene regulation.","date":"2007","source":"Neuron glia biology","url":"https://pubmed.ncbi.nlm.nih.gov/18634568","citation_count":65,"is_preprint":false},{"pmid":"30224375","id":"PMC_30224375","title":"UBE2N Promotes Melanoma Growth via MEK/FRA1/SOX10 Signaling.","date":"2018","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/30224375","citation_count":64,"is_preprint":false},{"pmid":"15896776","id":"PMC_15896776","title":"Co-expression of SOX9 and SOX10 during melanocytic differentiation in vitro.","date":"2005","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/15896776","citation_count":59,"is_preprint":false},{"pmid":"16330480","id":"PMC_16330480","title":"Deletion of long-range sequences at Sox10 compromises developmental expression in a mouse model of Waardenburg-Shah (WS4) syndrome.","date":"2005","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/16330480","citation_count":58,"is_preprint":false},{"pmid":"12490719","id":"PMC_12490719","title":"Cooperative binding of Sox10 to DNA: requirements and consequences.","date":"2002","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/12490719","citation_count":58,"is_preprint":false},{"pmid":"31881017","id":"PMC_31881017","title":"The MITF-SOX10 regulated long non-coding RNA DIRC3 is a melanoma tumour suppressor.","date":"2019","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/31881017","citation_count":57,"is_preprint":false},{"pmid":"19845757","id":"PMC_19845757","title":"Nestin and SOX9 and SOX10 transcription factors are coexpressed in melanoma.","date":"2010","source":"Experimental dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/19845757","citation_count":53,"is_preprint":false},{"pmid":"11113541","id":"PMC_11113541","title":"Expression of the Sox10 gene during mouse inner ear development.","date":"2000","source":"Brain research. Molecular brain research","url":"https://pubmed.ncbi.nlm.nih.gov/11113541","citation_count":51,"is_preprint":false},{"pmid":"34728538","id":"PMC_34728538","title":"SOX10 Regulates Melanoma Immunogenicity through an IRF4-IRF1 Axis.","date":"2021","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/34728538","citation_count":49,"is_preprint":false},{"pmid":"30713042","id":"PMC_30713042","title":"Sox10 Regulates Plasticity of Epithelial Progenitors toward Secretory Units of Exocrine Glands.","date":"2019","source":"Stem cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/30713042","citation_count":49,"is_preprint":false},{"pmid":"28370559","id":"PMC_28370559","title":"Transcription factor Sox10 regulates oligodendroglial Sox9 levels via microRNAs.","date":"2017","source":"Glia","url":"https://pubmed.ncbi.nlm.nih.gov/28370559","citation_count":48,"is_preprint":false},{"pmid":"31828317","id":"PMC_31828317","title":"Myrf guides target gene selection of transcription factor Sox10 during oligodendroglial development.","date":"2020","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/31828317","citation_count":46,"is_preprint":false},{"pmid":"12351187","id":"PMC_12351187","title":"Expression of Sox8, Sox9 and Sox10 in the developing valves and autonomic nerves of the embryonic heart.","date":"2002","source":"Mechanisms of development","url":"https://pubmed.ncbi.nlm.nih.gov/12351187","citation_count":46,"is_preprint":false},{"pmid":"25536222","id":"PMC_25536222","title":"SOX10 transactivates S100B to suppress Schwann cell proliferation and to promote myelination.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25536222","citation_count":45,"is_preprint":false},{"pmid":"16791471","id":"PMC_16791471","title":"Expression of SOX9 and SOX10 in central neuroepithelial tumor.","date":"2006","source":"Journal of neuro-oncology","url":"https://pubmed.ncbi.nlm.nih.gov/16791471","citation_count":44,"is_preprint":false},{"pmid":"20067553","id":"PMC_20067553","title":"PAX3 and SOX10 activate MET receptor expression in melanoma.","date":"2010","source":"Pigment cell & melanoma research","url":"https://pubmed.ncbi.nlm.nih.gov/20067553","citation_count":43,"is_preprint":false},{"pmid":"18923447","id":"PMC_18923447","title":"SOX9 and SOX10 but not BRN2 are required for nestin expression in human melanoma cells.","date":"2008","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/18923447","citation_count":40,"is_preprint":false},{"pmid":"25001176","id":"PMC_25001176","title":"SOX10 is a novel oncogene in hepatocellular carcinoma through Wnt/β-catenin/TCF4 cascade.","date":"2014","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25001176","citation_count":39,"is_preprint":false},{"pmid":"33085838","id":"PMC_33085838","title":"CircRNA EPHB4 modulates stem properties and proliferation of gliomas via sponging miR-637 and up-regulating SOX10.","date":"2020","source":"Molecular oncology","url":"https://pubmed.ncbi.nlm.nih.gov/33085838","citation_count":37,"is_preprint":false},{"pmid":"29181082","id":"PMC_29181082","title":"SOX10-MITF pathway activity in melanoma cells.","date":"2016","source":"Archives of medical science : AMS","url":"https://pubmed.ncbi.nlm.nih.gov/29181082","citation_count":36,"is_preprint":false},{"pmid":"23752089","id":"PMC_23752089","title":"Value of SOX10 immunostaining in tumor diagnosis.","date":"2013","source":"Advances in anatomic pathology","url":"https://pubmed.ncbi.nlm.nih.gov/23752089","citation_count":35,"is_preprint":false},{"pmid":"29315345","id":"PMC_29315345","title":"Identification and functional analysis of SOX10 phosphorylation sites in melanoma.","date":"2018","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/29315345","citation_count":32,"is_preprint":false},{"pmid":"34879275","id":"PMC_34879275","title":"SOX10 requirement for melanoma tumor growth is due, in part, to immune-mediated effects.","date":"2021","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/34879275","citation_count":32,"is_preprint":false},{"pmid":"28189679","id":"PMC_28189679","title":"SOX10 induced Nestin expression regulates cancer stem cell properties of TNBC cells.","date":"2017","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/28189679","citation_count":31,"is_preprint":false},{"pmid":"30498968","id":"PMC_30498968","title":"SOX10 Immunoexpression in Basaloid Squamous Cell Carcinomas: A Diagnostic Pitfall for Ruling out Salivary Differentiation.","date":"2018","source":"Head and neck pathology","url":"https://pubmed.ncbi.nlm.nih.gov/30498968","citation_count":31,"is_preprint":false},{"pmid":"37436963","id":"PMC_37436963","title":"Novel SOX10 indel mutations drive schwannomas through impaired transactivation of myelination gene programs.","date":"2023","source":"Neuro-oncology","url":"https://pubmed.ncbi.nlm.nih.gov/37436963","citation_count":30,"is_preprint":false},{"pmid":"23729567","id":"PMC_23729567","title":"Sox appeal - Sox10 attracts epigenetic and transcriptional regulators in myelinating glia.","date":"2013","source":"Biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23729567","citation_count":30,"is_preprint":false},{"pmid":"20890226","id":"PMC_20890226","title":"SOX10 expression in superficial spreading and nodular malignant melanomas.","date":"2010","source":"Melanoma research","url":"https://pubmed.ncbi.nlm.nih.gov/20890226","citation_count":30,"is_preprint":false},{"pmid":"34385359","id":"PMC_34385359","title":"Akt Regulates Sox10 Expression to Control Oligodendrocyte Differentiation via Phosphorylating FoxO1.","date":"2021","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/34385359","citation_count":30,"is_preprint":false},{"pmid":"34453037","id":"PMC_34453037","title":"SOX10 ablation severely impairs the generation of postmigratory neural crest from human pluripotent stem cells.","date":"2021","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/34453037","citation_count":28,"is_preprint":false},{"pmid":"36343245","id":"PMC_36343245","title":"SOX9 and SOX10 control fluid homeostasis in the inner ear for hearing through independent and cooperative mechanisms.","date":"2022","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/36343245","citation_count":27,"is_preprint":false},{"pmid":"19830815","id":"PMC_19830815","title":"Oligodendroglial and pan-neural crest expression of Cre recombinase directed by Sox10 enhancer.","date":"2009","source":"Genesis (New York, N.Y. : 2000)","url":"https://pubmed.ncbi.nlm.nih.gov/19830815","citation_count":27,"is_preprint":false},{"pmid":"23608456","id":"PMC_23608456","title":"Sox10 and Itgb1 interaction in enteric neural crest cell migration.","date":"2013","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/23608456","citation_count":26,"is_preprint":false},{"pmid":"31924335","id":"PMC_31924335","title":"Combined use of SOX10 and GATA3 in mammary carcinoma.","date":"2019","source":"Pathology, research and practice","url":"https://pubmed.ncbi.nlm.nih.gov/31924335","citation_count":26,"is_preprint":false},{"pmid":"17478888","id":"PMC_17478888","title":"Progesterone derivatives increase expression of Krox-20 and Sox-10 in rat Schwann cells.","date":"2007","source":"Journal of molecular neuroscience : MN","url":"https://pubmed.ncbi.nlm.nih.gov/17478888","citation_count":26,"is_preprint":false},{"pmid":"36848842","id":"PMC_36848842","title":"Molecular insights into effects of PBAT microplastics on latosol microbial diversity and DOM chemodiversity.","date":"2023","source":"Journal of hazardous materials","url":"https://pubmed.ncbi.nlm.nih.gov/36848842","citation_count":26,"is_preprint":false},{"pmid":"32899175","id":"PMC_32899175","title":"Immunohistological Expression of SOX-10 in Triple-Negative Breast Cancer: A Descriptive Analysis of 113 Samples.","date":"2020","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32899175","citation_count":25,"is_preprint":false},{"pmid":"38132479","id":"PMC_38132479","title":"Clinical Significance of SOX10 Expression in Human Pathology.","date":"2023","source":"Current issues in molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/38132479","citation_count":24,"is_preprint":false},{"pmid":"28098399","id":"PMC_28098399","title":"MYB, CD117 and SOX-10 expression in cutaneous adnexal tumors.","date":"2017","source":"Journal of cutaneous pathology","url":"https://pubmed.ncbi.nlm.nih.gov/28098399","citation_count":23,"is_preprint":false},{"pmid":"25256313","id":"PMC_25256313","title":"SOX10 mutations mimic isolated hearing loss.","date":"2014","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/25256313","citation_count":23,"is_preprint":false},{"pmid":"28751573","id":"PMC_28751573","title":"Sox10+ Cells Contribute to Vascular Development in Multiple Organs-Brief Report.","date":"2017","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/28751573","citation_count":23,"is_preprint":false},{"pmid":"30424592","id":"PMC_30424592","title":"PLAG1, SOX10, and Myb Expression in Benign and Malignant Salivary Gland Neoplasms.","date":"2018","source":"Journal of pathology and translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30424592","citation_count":22,"is_preprint":false},{"pmid":"24329979","id":"PMC_24329979","title":"SOX-10 expression in cutaneous myoepitheliomas and mixed tumors.","date":"2014","source":"Journal of cutaneous pathology","url":"https://pubmed.ncbi.nlm.nih.gov/24329979","citation_count":22,"is_preprint":false},{"pmid":"30506895","id":"PMC_30506895","title":"The myelin protein PMP2 is regulated by SOX10 and drives melanoma cell invasion.","date":"2018","source":"Pigment cell & melanoma research","url":"https://pubmed.ncbi.nlm.nih.gov/30506895","citation_count":22,"is_preprint":false},{"pmid":"29969627","id":"PMC_29969627","title":"The miR-31-SOX10 axis regulates tumor growth and chemotherapy resistance of melanoma via PI3K/AKT pathway.","date":"2018","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/29969627","citation_count":22,"is_preprint":false},{"pmid":"34159693","id":"PMC_34159693","title":"DNA-stable isotope probing (DNA-SIP) identifies marine sponge-associated bacteria actively utilizing dissolved organic matter (DOM).","date":"2021","source":"Environmental microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/34159693","citation_count":22,"is_preprint":false},{"pmid":"30950082","id":"PMC_30950082","title":"SOX-10 staining in dermal scars.","date":"2019","source":"Journal of cutaneous pathology","url":"https://pubmed.ncbi.nlm.nih.gov/30950082","citation_count":21,"is_preprint":false},{"pmid":"30903273","id":"PMC_30903273","title":"SOX10 expression in mammary invasive ductal carcinomas and benign breast tissue.","date":"2019","source":"Virchows Archiv : an international journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/30903273","citation_count":21,"is_preprint":false},{"pmid":"28394798","id":"PMC_28394798","title":"Sox10 and DOG1 Expression in Primary Adnexal Tumors of the Skin.","date":"2017","source":"The American Journal of dermatopathology","url":"https://pubmed.ncbi.nlm.nih.gov/28394798","citation_count":21,"is_preprint":false},{"pmid":"28071739","id":"PMC_28071739","title":"Sox10+ adult stem cells contribute to biomaterial encapsulation and microvascularization.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28071739","citation_count":20,"is_preprint":false},{"pmid":"29922125","id":"PMC_29922125","title":"Key Genes and Pathways Associated With Inner Ear Malformation in SOX10   Mutation Pigs.","date":"2018","source":"Frontiers in molecular neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/29922125","citation_count":20,"is_preprint":false},{"pmid":"27955842","id":"PMC_27955842","title":"Sox10 regulates skin melanocyte proliferation by activating the DNA replication licensing factor MCM5.","date":"2016","source":"Journal of dermatological science","url":"https://pubmed.ncbi.nlm.nih.gov/27955842","citation_count":19,"is_preprint":false},{"pmid":"28343365","id":"PMC_28343365","title":"SOX10 immunohistochemistry in sweat ductal/glandular neoplasms.","date":"2017","source":"Journal of cutaneous pathology","url":"https://pubmed.ncbi.nlm.nih.gov/28343365","citation_count":17,"is_preprint":false},{"pmid":"38430584","id":"PMC_38430584","title":"Spatial gradients and molecular transformations of DOM, DON and DOS in human-impacted estuarine sediments.","date":"2024","source":"Environment international","url":"https://pubmed.ncbi.nlm.nih.gov/38430584","citation_count":17,"is_preprint":false},{"pmid":"37343247","id":"PMC_37343247","title":"Targeting Upregulated cIAP2 in SOX10-Deficient Drug Tolerant Melanoma.","date":"2023","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/37343247","citation_count":17,"is_preprint":false},{"pmid":"22736149","id":"PMC_22736149","title":"Expression of Sox10 and c-kit in sinonasal mucosal melanomas arising in the Chinese population.","date":"2012","source":"Head and neck pathology","url":"https://pubmed.ncbi.nlm.nih.gov/22736149","citation_count":17,"is_preprint":false},{"pmid":"25611246","id":"PMC_25611246","title":"Can SOX-10 or KBA.62 Replace S100 Protein in Immunohistochemical Evaluation of Sentinel Lymph Nodes for Metastatic Melanoma?","date":"2016","source":"Applied immunohistochemistry & molecular morphology : AIMM","url":"https://pubmed.ncbi.nlm.nih.gov/25611246","citation_count":17,"is_preprint":false},{"pmid":"34099848","id":"PMC_34099848","title":"Functional in vivo characterization of sox10 enhancers in neural crest and melanoma development.","date":"2021","source":"Communications biology","url":"https://pubmed.ncbi.nlm.nih.gov/34099848","citation_count":17,"is_preprint":false},{"pmid":"37336549","id":"PMC_37336549","title":"SOX10.","date":"2023","source":"Journal of clinical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/37336549","citation_count":16,"is_preprint":false},{"pmid":"31222589","id":"PMC_31222589","title":"SOX10 and GATA3 in Adenoid Cystic Carcinoma and Polymorphous Adenocarcinoma.","date":"2019","source":"Head and neck pathology","url":"https://pubmed.ncbi.nlm.nih.gov/31222589","citation_count":16,"is_preprint":false},{"pmid":"33362852","id":"PMC_33362852","title":"Novel SOX10 Mutations in Waardenburg Syndrome: Functional Characterization and Genotype-Phenotype Analysis.","date":"2020","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/33362852","citation_count":16,"is_preprint":false},{"pmid":"25912689","id":"PMC_25912689","title":"The transcription factors Ets1 and Sox10 interact during murine melanocyte development.","date":"2015","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/25912689","citation_count":16,"is_preprint":false},{"pmid":"25265429","id":"PMC_25265429","title":"Sox10 is superior to S100 in the diagnosis of meningioma.","date":"2015","source":"Applied immunohistochemistry & molecular morphology : AIMM","url":"https://pubmed.ncbi.nlm.nih.gov/25265429","citation_count":16,"is_preprint":false},{"pmid":"32707054","id":"PMC_32707054","title":"Conjunctival nevi and melanoma: multiparametric immunohistochemical analysis, including p16, SOX10, HMB45, and Ki-67.","date":"2020","source":"Human pathology","url":"https://pubmed.ncbi.nlm.nih.gov/32707054","citation_count":15,"is_preprint":false},{"pmid":"36919939","id":"PMC_36919939","title":"Mechanism of SOX10 in ferroptosis of hippocampal neurons after intracerebral hemorrhage via the miR-29a-3p/ACSL4 axis.","date":"2023","source":"Journal of neurophysiology","url":"https://pubmed.ncbi.nlm.nih.gov/36919939","citation_count":15,"is_preprint":false},{"pmid":"35257758","id":"PMC_35257758","title":"Dissolved organic matter (DOM) was detected in MSWI plant: An investigation of DOM and potential toxic elements variation in the bottom ash and fly ash.","date":"2022","source":"The Science of the total environment","url":"https://pubmed.ncbi.nlm.nih.gov/35257758","citation_count":15,"is_preprint":false},{"pmid":"36198237","id":"PMC_36198237","title":"Comparative role of SOX10 gene in the gliogenesis of central, peripheral, and enteric nervous systems.","date":"2022","source":"Differentiation; research in biological diversity","url":"https://pubmed.ncbi.nlm.nih.gov/36198237","citation_count":14,"is_preprint":false},{"pmid":"33801642","id":"PMC_33801642","title":"SOX11, SOX10 and MITF Gene Interaction: A Possible Diagnostic Tool in Malignant Melanoma.","date":"2021","source":"Life (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/33801642","citation_count":14,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":47646,"output_tokens":7964,"usd":0.131199,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":17669,"output_tokens":8189,"usd":0.146535,"stage2_stop_reason":"end_turn"},"total_usd":0.277734,"stage1_batch_id":"msgbatch_013LWZZT6MWaqB9qyTSeQBmU","stage2_batch_id":"msgbatch_0194ZzQaTGNpruoNJBbEMbt3","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1998,\n      \"finding\": \"SOX10 functions as a transcriptional modulator in glial cells that lacks autonomous transcriptional activity but acts synergistically with the POU domain protein Tst-1/Oct6/SCIP; synergy depends on binding to adjacent sites in target promoters and is mediated by the N-terminal regions of both proteins. SOX10 also modulates the function of Pax3 and Krox-20.\",\n      \"method\": \"Functional transcription assays, promoter binding studies, synergy assays with deletion/domain mutants\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — direct functional assays with domain mapping, replicated across multiple transcription factor partners in the foundational paper\",\n      \"pmids\": [\"9412504\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Premature termination of SOX10 (Dom mutation) disrupts expression of both Sox10 and Ednrb in neural crest cells and causes loss of neural crest derivatives through apoptosis, establishing SOX10 as essential for peripheral nervous system development from the neural crest.\",\n      \"method\": \"Mouse genetic model (Dom mutation), in situ hybridization, apoptosis assays\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — loss-of-function mouse model with defined cellular phenotype (apoptosis of neural crest derivatives), widely replicated\",\n      \"pmids\": [\"9425902\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"SOX10 directly binds and activates transcription of the MITF promoter; a WS4-linked mutant form of SOX10 acts as a dominant-negative repressor of MITF expression and reduces endogenous MITF protein levels, providing a molecular basis for hypopigmentation and deafness in WS4.\",\n      \"method\": \"Promoter binding assays, transcriptional activation assays, dominant-negative mutant analysis, endogenous MITF protein measurement\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — direct binding to MITF promoter demonstrated, mutant dominant-negative activity shown, functional consequence (MITF protein reduction) confirmed\",\n      \"pmids\": [\"10973953\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"SOX10 binds DNA cooperatively as a dimer; specific amino acid residues immediately preceding the HMG domain are required for cooperative (dimeric) binding, which cooperates with the HMG domain in a manner dependent on determinants within the first two alpha-helices. Cooperative binding is essential for full activation of the myelin protein zero (Mpz) promoter.\",\n      \"method\": \"Mutagenesis of cooperative binding residues, DNA binding assays, promoter activation assays\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro DNA binding reconstitution plus mutagenesis and functional promoter assay, single lab but multiple orthogonal methods\",\n      \"pmids\": [\"12490719\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"SOX10 maintains multipotency of neural crest stem cells by preserving both glial and neuronal potential, is required in vivo for induction of neurogenic transcription factors MASH1 and PHOX2B, and simultaneously inhibits overt neuronal differentiation (requiring higher Sox10 gene dosage than multipotency maintenance).\",\n      \"method\": \"In vitro neural crest stem cell assays, in vivo genetic analysis, gene dosage experiments\",\n      \"journal\": \"Neuron\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — loss-of-function in vivo combined with in vitro dosage experiments, multiple orthogonal methods\",\n      \"pmids\": [\"12691661\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"SOX10 dimerization domain and a newly defined central transactivation domain have distinct roles: a functional dimerization domain is required for immature Schwann cells to enter the promyelinating stage, while the central transactivation domain is uniquely required for satellite glia differentiation and Schwann cell myelination but not for early neural crest or oligodendrocyte differentiation.\",\n      \"method\": \"Hypomorphic Sox10 alleles (triple alanine substitution in dimerization domain; deletion of central transactivation domain) in mice, phenotypic analysis\",\n      \"journal\": \"Development (Cambridge, England)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — two distinct hypomorphic alleles with domain-specific mutations analyzed in vivo, multiple cell-type phenotypes characterized\",\n      \"pmids\": [\"17699610\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"SOX10 and EGR2/Krox20 interact synergistically to activate the myelin protein zero (Mpz) gene; activation of the Mpz intronic element by Egr2 requires both Sox10-binding sites; Egr1 and Egr3 also cooperate with Sox10 at this element. Dominant EGR2 neuropathy mutations disrupt EGR2/SOX10 synergy.\",\n      \"method\": \"Reporter assays, mutagenesis of binding sites, co-activation assays with Egr family members\",\n      \"journal\": \"Neuron glia biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — functional promoter assays with mutagenesis of binding sites, multiple Egr family members tested, disease mutations validated\",\n      \"pmids\": [\"18634568\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Olig1 physically associates with Sox10, and the Olig1/Sox10 complex activates myelin basic protein (mbp) transcription via conserved DNA sequence motifs in the mbp promoter region. In contrast, Olig2 does not bind Sox10 in zebrafish (though both OLIG1 and OLIG2 bind SOX10 in mouse).\",\n      \"method\": \"Physical binding assay (association), transcriptional reporter assays with conserved mbp promoter motifs, zebrafish and mouse comparison\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — physical interaction demonstrated, functional promoter activation with defined binding sites, cross-species validation\",\n      \"pmids\": [\"18160645\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"SOX10 haploinsufficiency counteracts NRAS(Q61K)-driven congenital naevus and melanoma formation in vivo; SOX10 silencing in human melanoma cells suppresses neural crest stem cell properties, inhibits proliferation and cell survival, and abolishes tumor formation in vivo.\",\n      \"method\": \"Sox10 haploinsufficiency in genetic melanoma mouse model, SOX10 siRNA knockdown in human melanoma cells, in vivo tumor formation assays\",\n      \"journal\": \"Nature cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis in mouse model plus loss-of-function in human cells plus in vivo tumor assay, multiple orthogonal approaches\",\n      \"pmids\": [\"22772081\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Stable SOX10 knockdown in human melanoma cells causes G1 cell cycle arrest, induces senescence, reduces MITF expression, elevates p21WAF1 and p27KIP2, leads to hypophosphorylated RB, and reduces E2F1 levels. SOX10 haploinsufficiency also reduces melanoma initiation in the Grm1(Tg) transgenic mouse model.\",\n      \"method\": \"Stable SOX10 shRNA knockdown, cell cycle analysis, western blotting, mouse genetic model\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — stable knockdown with defined molecular readouts (p21, p27, RB phosphorylation, E2F1) plus in vivo mouse model validation\",\n      \"pmids\": [\"23913827\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"SOX10 directly binds and activates the MIA (melanoma inhibitory activity) promoter, as demonstrated by EMSA and ChIP; SOX10 inhibition reduces MIA expression and promoter activity, and ectopic MIA restores the invasion capacity of SOX10-inhibited melanoma cells, establishing MIA as a direct SOX10 target mediating invasion.\",\n      \"method\": \"RNA interference, EMSA, chromatin immunoprecipitation, luciferase reporter assays, invasion assays, rescue with ectopic MIA\",\n      \"journal\": \"The Journal of investigative dermatology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — direct binding shown by EMSA and ChIP, functional rescue experiment performed, multiple orthogonal methods in single lab\",\n      \"pmids\": [\"24608986\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"SOX9 is upregulated upon SOX10 loss in melanoma cells; SOX9 overexpression causes cell cycle arrest and apoptosis; SOX9 binds the SOX10 promoter and induces SOX10 downregulation, creating a feedback loop. SOX9 is required in vitro and in vivo for the anti-tumorigenic effect of SOX10 reduction.\",\n      \"method\": \"SOX10 knockdown, SOX9 overexpression, ChIP of SOX9 at SOX10 promoter, in vitro and in vivo tumor assays, epistasis experiments\",\n      \"journal\": \"PLoS genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP demonstrating SOX9 binding to SOX10 promoter, genetic epistasis in vivo, multiple orthogonal methods\",\n      \"pmids\": [\"25629959\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Sox10 is specifically expressed in mammary cells with the highest stem/progenitor activity; its deletion reduces stem/progenitor competence whereas overexpression increases stem/progenitor activity and causes a mesenchymal transition in mammary cells. SOX10 acts downstream of FGF signaling.\",\n      \"method\": \"Conditional Sox10 deletion, Sox10 overexpression, mammary stem cell functional assays, organoid assays\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain- and loss-of-function in vivo and in vitro with defined functional readouts, pathway placement via FGF signaling\",\n      \"pmids\": [\"26365194\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"SOX10 occupies genomic sites overlapping with active enhancers in both oligodendrocytes and Schwann cells; in oligodendrocytes, SOX10 binding sites co-occur with Olig2 and Myrf; in Schwann cells, SOX10 co-occupies sites with Egr2/Krox20. siRNA knockdown of nuclear receptors Nr2f1 and Nr2f2 reduces myelin gene expression (Mbp, Ndrg1) in Schwann cells, identifying them as SOX10 co-regulators.\",\n      \"method\": \"In vivo ChIP-Seq in spinal cord and sciatic nerve, transcriptome profiling, siRNA knockdown\",\n      \"journal\": \"Glia\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo ChIP-Seq with transcriptome profiling and functional siRNA validation, multiple cell types compared\",\n      \"pmids\": [\"25974668\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"CHD7 interacts with SOX10 and together they target enhancers of key myelinogenic genes; Chd7 is required for proper onset of CNS myelination and remyelination.\",\n      \"method\": \"Genome-wide occupancy analysis (ChIP), transcriptome profiling, genetic mouse models\",\n      \"journal\": \"Nature neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genome-wide ChIP showing physical co-occupancy, loss-of-function phenotype, transcriptome profiling\",\n      \"pmids\": [\"26928066\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Sox10 directly activates the DNA replication licensing factor MCM5 by binding to conserved SOX10 consensus sequences in the MCM5 promoter; MCM5 overexpression partially rescues the proliferation defect caused by Sox10 knockdown in melanocytes.\",\n      \"method\": \"Sox10 knockdown (RNAi), ChIP of SOX10 at MCM5 promoter, promoter reporter assays, MCM5 rescue experiments\",\n      \"journal\": \"Journal of dermatological science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — direct promoter binding by ChIP, functional rescue by target overexpression, multiple methods\",\n      \"pmids\": [\"27955842\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"SOX10 transcriptionally activates miR335 and miR338, which in turn recognize the 3'-UTR of Sox9 mRNA to reduce Sox9 protein levels post-transcriptionally in oligodendrocytes, creating an inverse coupling between Sox10 and Sox9 levels during oligodendrocyte differentiation.\",\n      \"method\": \"Sox10 deletion in oligodendroglial cells, miRNA expression analysis, 3'-UTR reporter assays, mathematical modeling\",\n      \"journal\": \"Glia\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — direct transcriptional target identification combined with 3'-UTR validation and genetic loss-of-function, multiple orthogonal methods\",\n      \"pmids\": [\"28370559\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"ERK1/2-mediated phosphorylation of SOX10 inhibits its transcriptional activity by interfering with sumoylation of SOX10 at K55, which is essential for its transcription activity. SOX10 activates FOXD3 transcription by binding a regulatory element in the FOXD3 promoter, completing an ERK1/2/SOX10/FOXD3/ERBB3 axis mediating adaptive resistance to RAF inhibitors.\",\n      \"method\": \"Phosphorylation site mutagenesis, sumoylation assays, ChIP and promoter binding assays, kinase inhibitor experiments, in vitro and in vivo knockdown\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct mutagenesis of phosphorylation (K55) and sumoylation sites, ChIP demonstrating promoter binding, multiple orthogonal methods in single lab\",\n      \"pmids\": [\"29295999\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"SOX10 directly regulates PMP2 (peripheral myelin protein 2), shown by ChIP, EMSA, and luciferase reporter assays; coregulation of PMP2 by SOX10 and EGR2 in melanoma cells was found; PMP2 expression increases melanoma cell invasion.\",\n      \"method\": \"RNA sequencing after SOX10 overexpression, ChIP, EMSA, luciferase reporter assays, invasion assays\",\n      \"journal\": \"Pigment cell & melanoma research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — direct binding to PMP2 regulatory elements shown by three independent methods (ChIP, EMSA, luciferase), functional invasion assay\",\n      \"pmids\": [\"30506895\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"SOX10 phosphorylation sites S24, S45, and T240 (within MAPK/CDK binding motifs) were identified by mass spectrometry and shown to affect SOX10 transcriptional activation on target promoters, subcellular localization, and protein stability in melanoma cells.\",\n      \"method\": \"Mass spectrometry phosphoproteomics, site-directed mutagenesis, transcriptional activation assays, subcellular localization imaging, protein stability assays\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 / Weak — mass spectrometry identification with mutagenesis follow-up, but single lab with limited functional depth per site\",\n      \"pmids\": [\"29315345\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Sox10 is essential for maintenance and differentiation of epithelial KIT+FGFR2b+ progenitors into secretory units (acinar, myoepithelial, and intercalated duct cells) in exocrine glands; genetic deletion of epithelial Sox10 leads to loss of secretory units; Sox10 overexpression in ductal progenitors enhances plasticity toward KIT+ progenitors and secretory unit differentiation.\",\n      \"method\": \"Genetic conditional deletion of Sox10 in epithelial cells, Sox10 overexpression, lineage tracing, organoid assays\",\n      \"journal\": \"Stem cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional genetic deletion and overexpression in vivo, multiple gland types examined, defined cellular phenotypes\",\n      \"pmids\": [\"30713042\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Myrf cooperates with Sox10 to induce genes required for oligodendrocyte differentiation and myelin formation through joint binding to the same regulatory regions; Myrf also inhibits Sox10 activity on earlier oligodendroglial genes through physical interaction with Sox10 followed by sequestration (on genes lacking Myrf binding sites).\",\n      \"method\": \"ChIP-Seq for binding site characterization, co-immunoprecipitation/physical interaction assays, transcriptional reporter assays, mutagenesis of Myrf DNA-binding sites\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — genome-wide binding site analysis combined with physical interaction and functional reporter assays, two distinct mechanisms defined\",\n      \"pmids\": [\"31828317\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Akt phosphorylates FoxO1, and phosphorylated FoxO1 is required for Sox10 promoter activity; Akt triple knockout in oligodendrocyte lineage cells causes complete loss of mature oligodendrocytes with downregulation of Sox10, and mutant FoxO1 without Akt phosphorylation epitopes is enriched at the Sox10 promoter.\",\n      \"method\": \"Oligodendrocyte-specific Akt1/2/3 triple conditional knockout mice, FoxO1 phospho-site mutagenesis, Sox10 promoter activity assays, ChIP of FoxO1 at Sox10 promoter\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — conditional triple knockout mouse model, FoxO1 mutagenesis at Akt phosphorylation sites, ChIP at Sox10 promoter, multiple orthogonal methods\",\n      \"pmids\": [\"34385359\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"SOX10 represses IRF1 transcription via direct induction of the negative regulator IRF4, establishing a SOX10-IRF4-IRF1 axis that regulates PD-L1 expression independently of the JAK-STAT pathway in melanoma cells.\",\n      \"method\": \"Genetic and pharmacologic SOX10 loss-of-function, IRF4 and IRF1 expression analysis, PD-L1 regulation assays\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic and pharmacologic approaches in single lab; direct binding of SOX10 to IRF4 regulatory elements not explicitly demonstrated in the abstract\",\n      \"pmids\": [\"34728538\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"SOX10 positively regulates HVEM and CEACAM1 expression in melanoma; Sox10 knockout reduces tumor growth in immune-competent models in a manner dependent partly on CD8+ T cells, demonstrating that SOX10 controls immune checkpoint protein expression and anti-tumor immunity.\",\n      \"method\": \"Sox10 knockout mouse models (immune-competent and immune-deficient), CD8+ T cell depletion, CEACAM1 and HVEM expression modulation\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo Sox10 knockout with immune cell depletion epistasis, but direct transcriptional regulation of HVEM/CEACAM1 by SOX10 not demonstrated mechanistically\",\n      \"pmids\": [\"34879275\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Recurrent in-frame insertion/deletion mutations in SOX10 found in schwannomas retain DNA binding capacity but have impaired transactivation of glial differentiation and myelination gene programs, driving schwannoma formation by impeding Schwann cell differentiation.\",\n      \"method\": \"ChIP-Seq, EMSA, luciferase reporter assays, RNA sequencing in fetal glial cells transduced with wild-type and mutant SOX10\",\n      \"journal\": \"Neuro-oncology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — multiple orthogonal methods (ChIP-Seq, EMSA, luciferase, RNA-Seq) directly testing mutant versus wild-type SOX10 function in the same study\",\n      \"pmids\": [\"37436963\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"SOX10 modulates expression of β1-integrins (Itgb1) in enteric neural crest cells; double mutants for Sox10 and beta1-integrin show increased intestinal aganglionosis and impaired enteric neural crest cell migration with reduced speed and altered directionality, indicating SOX10 mediates enteric neural crest cell adhesion and migration through β1-integrin regulation.\",\n      \"method\": \"Genetic double mutant mouse analysis, video-microscopy of cell migration, β1-integrin expression analysis upon SOX10 modulation\",\n      \"journal\": \"Developmental biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis in double-mutant mouse model with live cell migration imaging, but direct transcriptional regulation of Itgb1 by SOX10 not fully established\",\n      \"pmids\": [\"23608456\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"SOX10 directly activates the S100B promoter through three core response elements with SOX motifs in the S100B promoter and intron 1; SOX10 knockdown suppresses S100B expression and enhances Schwann cell proliferation; S100B knockdown impairs myelination in dorsal root ganglia co-cultures.\",\n      \"method\": \"SOX10 overexpression/knockdown, promoter deletion/mutation analysis identifying SOX10 response elements, shRNA knockdown of S100B, DRG myelination assay\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — direct identification of three SOX10 response elements in S100B promoter/intron1, gain/loss-of-function with functional myelination readout\",\n      \"pmids\": [\"25536222\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"SOX10 binds the miR-29a-3p promoter region to increase miR-29a-3p expression; miR-29a-3p in turn targets and limits ACSL4 transcription, thereby inhibiting ferroptosis of hippocampal neurons in an ICH model.\",\n      \"method\": \"ChIP assay, dual-luciferase reporter assays, miR-29a-3p overexpression/knockdown, ACSL4 expression analysis, ferroptosis assays\",\n      \"journal\": \"Journal of neurophysiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 / Weak — ChIP and dual-luciferase confirm SOX10 binding to miR-29a-3p promoter, but single lab, in vitro ICH model only\",\n      \"pmids\": [\"36919939\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Genetic interaction analysis of Sox10 with Ednrb and Edn3 double mutant mice shows that balanced Sox10 and endothelin signaling is required for normal ENS and melanocyte development; partial loss of Ednrb in Sox10 heterozygous mice impairs colonisation of the gut by enteric crest cells without increasing apoptosis or altering differentiation, indicating a migration/survival role.\",\n      \"method\": \"Sox10;Ednrb and Sox10;Edn3 double mutant mouse phenotype analysis, apoptosis assays, cell proliferation assays, differentiation marker analysis\",\n      \"journal\": \"Developmental biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis using double mutant mice with multiple cellular readouts, but mechanistic link between SOX10 and Ednrb signaling not defined at molecular level\",\n      \"pmids\": [\"16650841\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"A 15.9 kb deletion 47.3 kb upstream of Sox10 removes conserved non-coding sequences with strong enhancer potential in melanocytes and reduces Sox10 expression in vivo, causing an enteric aganglionosis and melanocyte loss phenotype (WS4-like), establishing that long-range regulatory elements are required for Sox10 expression.\",\n      \"method\": \"Comparative genomic sequence analysis, in vitro enhancer assay in melanocytes, transgene-insertion mouse model with Sox10 expression analysis\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo deletion model with expression analysis and in vitro enhancer validation, but enhancer assignment is partial\",\n      \"pmids\": [\"16330480\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"In vivo ATAC-Seq of zebrafish melanoma tumors identified recurrently open chromatin domains as sox10 enhancers; a conserved ~200 bp region 23 kb upstream of sox10 (peak5) containing dimeric SoxE/Sox10 binding sites drives expression in neural crest and melanoma; deletion of the endogenous peak5 locus decreases embryonic sox10 expression and disrupts adult stripe patterning.\",\n      \"method\": \"ATAC-Seq, EGFP reporter assays in vivo, binding site mutagenesis, endogenous locus deletion in zebrafish\",\n      \"journal\": \"Communications biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — ATAC-Seq combined with in vivo reporter, binding site mutagenesis, and endogenous locus deletion, multiple orthogonal methods\",\n      \"pmids\": [\"34099848\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Ets1 activates an enhancer critical for Sox10 expression in neural crest-derived structures; this activation is inhibited by the variable spotting Ets1 G102E mutation; Ets1 and Sox10 interact synergistically in melanocyte and enteric ganglia development (double heterozygotes show greater hypopigmentation than additive effects of single heterozygotes).\",\n      \"method\": \"Genetic epistasis (double heterozygous mice), enhancer reporter assays, mutation analysis\",\n      \"journal\": \"Developmental biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis in mouse model with functional enhancer validation, but direct Ets1-Sox10 protein interaction not demonstrated\",\n      \"pmids\": [\"25912689\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"SOX10 is a dimerizing HMG-box transcription factor that acts as a context-dependent transcriptional activator and co-regulator: it directly binds target gene promoters/enhancers (MITF, Mpz, MBP, MIA, PMP2, S100B, MCM5, FOXD3, miR-29a-3p) to activate transcription, cooperates synergistically with cell-type-specific partners (Oct6/SCIP, Olig1, EGR2, Myrf, CHD7) through protein–protein interactions that require its N-terminal and central transactivation domains, and is regulated post-translationally by ERK-mediated phosphorylation (which blocks sumoylation at K55, reducing transcriptional activity) and by Akt-dependent FoxO1 phosphorylation (which controls Sox10 promoter activity); its dimeric DNA-binding mode requires conserved residues flanking the HMG domain and is essential for full target gene activation; loss of SOX10 in neural crest progenitors causes apoptosis and loss of PNS/melanocyte derivatives, while in differentiated glia it controls the switch from oligodendrocyte precursor to myelinating states partly through transcriptional upregulation of miR335/miR338 that reciprocally suppress Sox9.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"SOX10 is a dimerizing HMG-box transcription factor that governs the specification, survival, and differentiation of neural crest derivatives and their glial and melanocytic progeny [#1, #4]. In neural crest stem cells it preserves multipotency and is required for induction of neurogenic factors MASH1 and PHOX2B, while its loss triggers apoptosis and depletion of peripheral nervous system and melanocyte lineages [#1, #4]. SOX10 has little autonomous transactivation capacity and operates combinatorially, binding adjacent promoter/enhancer sites and acting synergistically with cell-type-specific partners through its N-terminal and central transactivation domains: Oct6/SCIP, Pax3 and Krox20 in glia [#0], EGR2/Krox20 and the nuclear receptors NR2F1/NR2F2 at Schwann-cell myelin genes [#6, #13], Olig1 and the chromatin remodeler CHD7 at oligodendrocyte myelin enhancers [#7, #14], and Myrf, which both co-activates late myelination genes and sequesters SOX10 from earlier oligodendroglial targets [#21]. Its DNA-binding is cooperative and dimeric, requiring residues flanking the HMG domain; this dimerization is essential for full activation of the myelin protein zero (Mpz) promoter and for Schwann cells to enter the promyelinating stage, whereas a distinct central transactivation domain is uniquely needed for satellite glia and Schwann cell myelination [#3, #5]. SOX10 directly activates an extended target repertoire including MITF, MBP, MIA, PMP2, S100B, MCM5, FOXD3, and the microRNAs miR335/miR338 (which reciprocally suppress Sox9) and miR-29a-3p, thereby controlling pigmentation, myelin gene programs, proliferation, and lineage stability [#2, #7, #10, #15, #16, #17, #18, #27, #28]. SOX10 activity is post-translationally tuned: ERK1/2 phosphorylation blocks sumoylation at K55 to dampen transcriptional output as part of an ERK/SOX10/FOXD3/ERBB3 axis driving RAF-inhibitor resistance, and Akt-dependent FoxO1 phosphorylation controls Sox10 promoter activity in the oligodendrocyte lineage [#17, #22]. In disease, dominant-negative WS4-linked mutants repress MITF [#2], SOX10 is a melanoma dependency whose loss induces senescence and engages a counter-regulatory SOX9 loop [#8, #9, #11], and recurrent indel mutations that retain DNA binding but lose transactivation drive schwannoma by blocking glial differentiation [#25].\",\n  \"teleology\": [\n    {\n      \"year\": 1998,\n      \"claim\": \"Established that SOX10 is not an autonomous activator but a combinatorial transcriptional modulator, reframing how its glial gene control should be understood.\",\n      \"evidence\": \"Transcription and synergy assays with domain-deletion mutants and POU partner Tst-1/Oct6/SCIP in glial cells\",\n      \"pmids\": [\"9412504\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define the full set of synergistic partners\", \"N-terminal interaction surface mapped only coarsely\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Demonstrated that SOX10 is essential for neural crest derivative survival, establishing its developmental requirement in PNS formation.\",\n      \"evidence\": \"Dom premature-termination mutation in mice with in situ hybridization and apoptosis assays\",\n      \"pmids\": [\"9425902\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanistic basis of apoptosis not resolved\", \"Relationship to Ednrb regulation correlative\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Identified MITF as a direct SOX10 target and provided the molecular basis for WS4 pigmentation/deafness via dominant-negative mutant action.\",\n      \"evidence\": \"MITF promoter binding and activation assays plus dominant-negative WS4 mutant analysis and endogenous MITF measurement\",\n      \"pmids\": [\"10973953\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Other WS4-relevant targets not addressed\", \"Cofactor requirements at MITF promoter not defined\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Defined the cooperative dimeric DNA-binding mode and showed it is required for full myelin gene activation, explaining a key biochemical feature of SOX10 function.\",\n      \"evidence\": \"Mutagenesis of residues flanking the HMG domain with DNA-binding and Mpz promoter assays\",\n      \"pmids\": [\"12490719\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural model of the dimer not determined\", \"In vivo requirement tested only later\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Showed SOX10 maintains neural crest multipotency in a dosage-dependent manner, separating its stem-cell maintenance role from differentiation control.\",\n      \"evidence\": \"In vitro NCSC assays and in vivo gene-dosage genetics with MASH1/PHOX2B readouts\",\n      \"pmids\": [\"12691661\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct targets mediating multipotency not identified\", \"Dosage thresholds molecularly undefined\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Demonstrated that long-range upstream enhancers are required for proper Sox10 expression, expanding the disease model beyond coding mutations.\",\n      \"evidence\": \"15.9 kb upstream deletion mouse model with enhancer assays and expression analysis\",\n      \"pmids\": [\"16330480\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Enhancer assignment partial\", \"Trans-factors binding the enhancer not fully identified\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Placed SOX10 in balanced cooperation with endothelin signaling for enteric and melanocyte development, implicating migration/survival rather than differentiation.\",\n      \"evidence\": \"Sox10;Ednrb and Sox10;Edn3 double-mutant mouse analysis with apoptosis/proliferation/differentiation readouts\",\n      \"pmids\": [\"16650841\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular link between SOX10 and endothelin signaling undefined\", \"Direct transcriptional connection not shown\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Separated SOX10 dimerization and central transactivation domains as functionally distinct, mapping which glial transitions each domain controls.\",\n      \"evidence\": \"Two hypomorphic Sox10 alleles (dimerization triple-alanine; central TAD deletion) analyzed in mice\",\n      \"pmids\": [\"17699610\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Domain-specific cofactor partners not fully resolved\", \"Direct targets per domain not enumerated\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Established EGR2/SOX10 synergy at the Mpz gene and linked dominant EGR2 neuropathy mutations to disrupted synergy, providing a mechanistic disease readout.\",\n      \"evidence\": \"Reporter assays with binding-site mutagenesis and co-activation with Egr family members\",\n      \"pmids\": [\"18634568\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physical EGR2-SOX10 contact surface not mapped\", \"Genome-wide co-targets defined only later\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Identified Olig1 as a physical SOX10 partner activating mbp, revealing a CNS-specific cooperative module distinct from the Schwann-cell program.\",\n      \"evidence\": \"Physical association assays and mbp reporter assays with conserved motifs, zebrafish/mouse comparison\",\n      \"pmids\": [\"18160645\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Species difference in Olig2 binding unexplained\", \"Stoichiometry of the complex unknown\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Established SOX10 as a melanoma dependency required for tumor formation and neural crest stem-cell properties, extending its developmental role to cancer.\",\n      \"evidence\": \"Sox10 haploinsufficiency in NRAS(Q61K) mouse model plus siRNA knockdown and in vivo tumor assays in human cells\",\n      \"pmids\": [\"22772081\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct effector targets of the tumor phenotype not fully defined here\", \"Mechanism of stem-cell property maintenance unresolved\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Defined the cell-cycle consequences of SOX10 loss in melanoma (G1 arrest, senescence, p21/p27 induction, RB hypophosphorylation), connecting SOX10 to proliferative control.\",\n      \"evidence\": \"Stable shRNA knockdown with cell-cycle and western analyses plus Grm1(Tg) mouse model\",\n      \"pmids\": [\"23913827\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct vs indirect regulation of cell-cycle effectors not separated\", \"MITF dependence of the arrest not fully dissected\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Linked SOX10 to enteric neural crest migration through β1-integrin regulation, framing a cell-adhesion/migration function.\",\n      \"evidence\": \"Sox10;Itgb1 double-mutant mice with video-microscopy of migration\",\n      \"pmids\": [\"23608456\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct transcriptional regulation of Itgb1 not established\", \"Genetic interaction may be indirect\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Identified MIA as a direct SOX10 target mediating melanoma invasion, providing a functional rescue-validated invasion effector.\",\n      \"evidence\": \"EMSA, ChIP, luciferase, invasion assays with ectopic MIA rescue\",\n      \"pmids\": [\"24608986\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cofactors at the MIA promoter not defined\", \"In vivo invasion contribution not tested\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Established S100B as a direct SOX10 target through defined response elements, linking SOX10 to Schwann cell proliferation control and myelination.\",\n      \"evidence\": \"Promoter/intron deletion-mutation mapping, gain/loss-of-function, and DRG myelination co-culture\",\n      \"pmids\": [\"25536222\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"S100B downstream signaling in myelination not fully resolved\", \"In vivo requirement not tested\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Mapped SOX10 genome-wide enhancer occupancy in two glial lineages and identified lineage-specific co-regulators (Olig2/Myrf vs Egr2; NR2F1/2), unifying its cell-type-specific partnerships.\",\n      \"evidence\": \"In vivo ChIP-Seq in spinal cord and sciatic nerve with transcriptome profiling and siRNA validation\",\n      \"pmids\": [\"25974668\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct vs cooperative binding contributions not parsed at all sites\", \"NR2F1/2 contact with SOX10 not biochemically shown\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Established a SOX10-SOX9 reciprocal feedback loop as the basis of the anti-tumorigenic effect of SOX10 loss in melanoma.\",\n      \"evidence\": \"SOX10 knockdown, SOX9 overexpression, ChIP of SOX9 at SOX10 promoter, in vivo epistasis\",\n      \"pmids\": [\"25629959\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How SOX10 normally restrains SOX9 transcriptionally not fully defined\", \"Generality across melanoma subtypes untested\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Extended SOX10 function to mammary epithelial stem/progenitor competence downstream of FGF signaling, broadening its role beyond neural crest lineages.\",\n      \"evidence\": \"Conditional deletion and overexpression with mammary stem-cell and organoid assays\",\n      \"pmids\": [\"26365194\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct SOX10 targets in mammary cells not identified\", \"Mechanism of FGF-to-SOX10 coupling unresolved\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Showed Ets1 activates a neural-crest Sox10 enhancer and interacts synergistically with Sox10, identifying an upstream regulatory input.\",\n      \"evidence\": \"Double-heterozygous mice, enhancer reporter assays, G102E mutation analysis\",\n      \"pmids\": [\"25912689\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct Ets1-Sox10 protein interaction not demonstrated\", \"Synergy mechanism molecularly undefined\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Identified MCM5 as a direct SOX10 target linking SOX10 to DNA replication licensing and melanocyte proliferation.\",\n      \"evidence\": \"RNAi knockdown, ChIP at MCM5 promoter, reporter assays, MCM5 rescue\",\n      \"pmids\": [\"27955842\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Other replication targets not surveyed\", \"In vivo proliferation contribution untested\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Established CHD7 as a SOX10 chromatin-remodeling partner at myelinogenic enhancers required for CNS myelination and remyelination.\",\n      \"evidence\": \"Genome-wide ChIP co-occupancy, transcriptome profiling, genetic mouse models\",\n      \"pmids\": [\"26928066\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Biochemical SOX10-CHD7 contact not mapped\", \"Remyelination mechanism not fully dissected\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Revealed that SOX10 activates miR335/miR338 to post-transcriptionally suppress Sox9, formalizing an inverse Sox10-Sox9 coupling during oligodendrocyte differentiation.\",\n      \"evidence\": \"Sox10 deletion in oligodendroglia, miRNA profiling, 3'-UTR reporters, mathematical modeling\",\n      \"pmids\": [\"28370559\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct vs indirect miRNA promoter activation not fully separated\", \"In vivo necessity of the loop untested\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Defined ERK1/2 phosphorylation as a switch that blocks K55 sumoylation to suppress SOX10 activity, and placed SOX10/FOXD3 in a RAF-inhibitor resistance axis.\",\n      \"evidence\": \"Phospho- and sumo-site mutagenesis, ChIP, kinase inhibitors, in vitro/in vivo knockdown\",\n      \"pmids\": [\"29295999\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry of phospho-sumo crosstalk in vivo unquantified\", \"Other sumoylation-dependent targets not surveyed\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Identified PMP2 as a direct SOX10/EGR2 co-target promoting melanoma invasion, extending myelin-gene regulation into the tumor context.\",\n      \"evidence\": \"RNA-Seq after overexpression, ChIP, EMSA, luciferase, invasion assays\",\n      \"pmids\": [\"30506895\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo invasion role untested\", \"Mechanism of PMP2-driven invasion undefined\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Mapped additional SOX10 phosphosites (S24, S45, T240) affecting activity, localization, and stability, broadening the post-translational regulatory map.\",\n      \"evidence\": \"Mass spectrometry phosphoproteomics, site mutagenesis, activity/localization/stability assays\",\n      \"pmids\": [\"29315345\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Limited functional depth per site\", \"Responsible kinases not definitively assigned\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Showed Myrf has a dual cooperative/sequestering relationship with SOX10, explaining how the same factor can both promote late and inhibit early oligodendroglial gene programs.\",\n      \"evidence\": \"ChIP-Seq, co-immunoprecipitation, reporter assays, Myrf binding-site mutagenesis\",\n      \"pmids\": [\"31828317\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of sequestration unknown\", \"Quantitative balance between modes in vivo unresolved\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Demonstrated SOX10 is required for exocrine gland epithelial KIT+FGFR2b+ progenitor maintenance and secretory differentiation, generalizing its progenitor-control function.\",\n      \"evidence\": \"Conditional deletion and overexpression with lineage tracing and organoids\",\n      \"pmids\": [\"30713042\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct epithelial SOX10 targets not identified\", \"FGFR2b-SOX10 coupling mechanism undefined\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Identified an Akt-FoxO1 input controlling Sox10 promoter activity required for oligodendrocyte maturation, defining an upstream signaling control of SOX10 expression.\",\n      \"evidence\": \"Oligodendrocyte Akt1/2/3 triple knockout, FoxO1 phospho-site mutagenesis, ChIP at Sox10 promoter\",\n      \"pmids\": [\"34385359\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How phospho-FoxO1 enables Sox10 transcription mechanistically unclear\", \"Other Akt targets contributing not excluded\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Linked SOX10 to immune evasion via a SOX10-IRF4-IRF1 axis regulating PD-L1 independently of JAK-STAT.\",\n      \"evidence\": \"Genetic and pharmacologic SOX10 loss with IRF4/IRF1 and PD-L1 readouts\",\n      \"pmids\": [\"34728538\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct SOX10 binding to IRF4 regulatory elements not shown\", \"In vivo immune relevance addressed separately\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Showed SOX10 controls immune checkpoint proteins HVEM/CEACAM1 and CD8+ T-cell-dependent tumor growth, connecting SOX10 to anti-tumor immunity.\",\n      \"evidence\": \"Sox10 knockout in immune-competent/deficient mice with CD8+ depletion and checkpoint modulation\",\n      \"pmids\": [\"34879275\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct transcriptional regulation of HVEM/CEACAM1 not demonstrated\", \"Mechanism of immune coupling indirect\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Identified an upstream peak5 enhancer with dimeric SoxE binding sites driving sox10 in neural crest and melanoma, linking enhancer regulation to pigment patterning and tumor chromatin state.\",\n      \"evidence\": \"ATAC-Seq, in vivo EGFP reporters, binding-site mutagenesis, endogenous locus deletion in zebrafish\",\n      \"pmids\": [\"34099848\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mammalian conservation of peak5 not established here\", \"Trans-factors beyond SoxE not fully defined\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Established that recurrent SOX10 indel mutations retain DNA binding but lose transactivation to block Schwann cell differentiation, defining a schwannoma driver mechanism.\",\n      \"evidence\": \"ChIP-Seq, EMSA, luciferase, RNA-Seq comparing wild-type and mutant SOX10 in fetal glial cells\",\n      \"pmids\": [\"37436963\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cofactor loss underlying transactivation defect not pinpointed\", \"In vivo tumorigenesis from these alleles untested\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Showed SOX10 binds the miR-29a-3p promoter to suppress ACSL4 and limit neuronal ferroptosis, extending SOX10 regulation to a neuroprotective miRNA axis.\",\n      \"evidence\": \"ChIP, dual-luciferase, miR-29a-3p gain/loss, ACSL4 and ferroptosis assays in an ICH model\",\n      \"pmids\": [\"36919939\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab in vitro ICH model only\", \"In vivo relevance not established\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How SOX10's combinatorial partner choice, dimeric binding, and post-translational modification state are integrated to select between progenitor-maintenance, myelination, and oncogenic gene programs in a given cell remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model linking phospho/sumo state to partner selection\", \"Structural basis of context-specific complexes undefined\", \"Quantitative dosage thresholds across lineages not mapped\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 2, 6, 7, 10, 15, 16, 17, 18, 21, 25, 27, 28]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [2, 3, 10, 15, 18, 25, 27, 31]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [17, 19]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0, 2, 6, 7, 16, 17, 21]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [1, 4, 5, 20, 27]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [2, 8, 9, 11, 25]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"EGR2\", \"OLIG1\", \"MYRF\", \"CHD7\", \"OCT6/POU3F1\", \"PAX3\", \"NR2F1\", \"SOX9\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}